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Abstract 
p16 and p15, both encoded by the genes located on chromosome 9p21, are 
inhibitors of cyclin-dependent kinases CDK4/6 and the up-stream regulators of Rb 
function. Alterations of p16/p15 have been commonly described in hematopoietic 
malignancies, particularly lymphoid and B-Iineage origin. However, the involvement 
of these two genes in multiple myeloma ( M M ) has not been reported. The aims of 
our current study are (1) To investigate whether these cell cycle-related genes {Rb, 
p16 and p15) functioning in the G1-S transition are altered in M M and (2) To 
evaluate their potential roles in M M pathogenesis through the analysis of dinico-
pathologic correlation. 
By a combination of Southern blot hybridization and Polymerase Chain 
Reaction- Single Strand Conformation Polymorphism ( P C R - S S C P ) analysis, w e 
observed, consistent with findings in the literature, no deletions or mutations of p16 
and p15 and no homozygous deletions or gene rearrangements of Rb in our twenty-
four M M patients analyzed. However, hypermethylation w a s observed in 6 7 % for 
Pl6 and 5 8 % for p15 in our group of relatively high stage M M patients. Such high 
frequencies of involvement of these genes in M M m a k e them hitherto the most 
c o m m o n genetic abnormalities in this disease. Although expression studies were 
not performed, our findings of reciprocal genetic alterations in Rb and p16/p15 are in 
line with observations m a d e on other solid tumors involving these genes. 
A significant correlation (p=0.026) between the blastic disease and 
hypermethylation of p16 gene w a s also demonstrated. T h e fact that 
hypermethylation of p16/p15 w a s found in both low and high stage patients and in 
similar incidences in pre- and post-treated groups m a y suggest they are early events 
and their role in tumor initiation can be speculated. Concomitant hypermethylation of 
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p16 and p15, u n c o m m o n thus far in the literature of the study of these genes, is a 
rather c o m m o n phenomenon, occurring in 5 4 % of our patients. Since all three 
patients (100%) having plasmacytomas were found to have concomitant 
hypermethylation of both p16 and p15 genes while this would only be seen in 4 8 % of 
the non-plasmacytoma group (n=21), this m a y suggest that concomitant 
hypermethylation of both genes m a y be pathogenetically related to plasmacytoma 
development. 
Our study is the first demonstration that alterations of p16 and p15 are 
involved in high incidences of M M , not by homozygous deletions or mutations, but 
solely by hypermethylation of 5'CpG islands which m a y be a specific mechanism in 
this disease. With the sensitive methylation-specific P C R (MS-PCR) technique 
developed recently, the methylation status in M M m a y serve as a tumor marker for 
the detection of minimal residual disease and evaluation of tumor contamination in 
the autologous graft in autologous bone marrow transplantation. Therapeutic 
innovations in drug development and processing of marrow or peripheral stem cell 
grafts resulted from information of this study m a y be speculative at this stage but 
effective in future. 
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多發性骨髓瘤的_抑制基因硏究 
摘 要 
?16和？15蛋白，被位於九號染色體短臂二區、一帶的基因編碼，是0701力依賴性激 
酵素00似/6的抑制者和[^1)功能的調節者。卩16/「15的改變在血液惡性腫瘤中，特別是 
在淋巴及8細胞源性惡性腫瘤中已被廣泛描述。但是，在多發性骨髓瘤中’這兩個基因 
是否參與尙未報到。本硏究的目的是：（1)調查在多發性骨髓瘤中，這些在01-3過渡期 
有功能的細胞周期相關性基因（Rb，「16和口15)的改變；（2)通過臨床和病理關係的分 
析，評估他們在多發性骨髓瘤中的潛在角色。 
通過30口1[16[11 13|01雜交和聚合酵素鏈式反應一單鏈構象多態性分析(口08-850?) ’ 
我們觀察所得’與文獻記載的發現一致’就是在分析的24例多發性骨髓瘤中’沒有口16 
和卩15的缺失和突變，及8&的同源重組。然而，在晚期的多發性骨髓瘤中’我們觀察 
到67%的「16和58%的「15存在高度甲基化。在多發性骨髓瘤中’這些基因如此高頻的 
參與，使它們成爲該病最普遍的遺傳改變。盡管未做表達性的硏究，我們發現的8匕和 
916/?15遺傳改變的相反關係模式，與這些基因在實體瘤中的表現相一致。 
髓性疾病與？16基因的高度甲基化呈現高度的相關性(？=0.026)。？16/?15的高度甲 
基化在疾病的晚期和早期，治療前後的病人中均具有相似的頻率，可建議甲基化爲早期 
事件’並且推測其在腫瘤發生中起始動作用。卩16和1^15的共甲基化的情形在目前關於 
這些基因的研究中並不普遍’但在我們的病人中卻普遍存在，佔54%。因爲全部三個 
(100%)伴有漿細胞瘤的病人均存有「16和「15共高度甲基化，而在非伴有漿細胞瘤組中 
(n=21) ’僅有48%顯示共高度甲基化，這可建議兩個基因的共同高度甲基化可能和漿細 
胞瘤的病因學有關。 
我們的硏究首次揭示了口16和915的高頻改變參與了多發性骨髓瘤的發生。這些改 
變’不是由缺失或突變造成’而單是由5|09〇島的高度甲基化所導致。此改變或許是該 
病發生的一個特定機制。利用近來發展之敏感的甲基化特異性聚合酵素鏈式反應(MS-
•^06)技術’甲基化的狀態可以成爲檢查微小殘餘疾病和評價在骨髓移植中’自家移植 
物的腫瘤污染之標志物。在藥物開發，及處理骨髓或外周幹細胞移植物方面，本研究所 
提供的信息可導致新治療方法的發明，在現階段或許是推測’但於將來，可以實現。 
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Chapter 1 
Introduction 
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1.1 Multiple Myeloma 
Multiple myeloma ( M M ) is a relatively rare clonal B-cell neoplasm 
characterized by skeletal dissemination of malignant plasma cells that 
accumulate in bone marrow and secrete monoclonal immunoglobulin (lg), the 
paraprotein. The skeletal involvement is mainly in axial skeleton, manifested as 
osteolytic lesions in skull, vertebrae and pelvic bones that cause pain and 
pathological fractures. Patients with early stages of M M m a y be asymptomatic 
and anaemia, infections, bone pain or fractures, renal failures or rarely bleeding 
tendency m a y develop at later stages and are the first presenting features at 
diagnosis. T h e homogeneous monoclonal immunoglobulins or lg fragments, 
known collectively as M components detected by immuno-electrophoresis, are 
composed of a single heavy chain class and a single light chain class. Ninety-
nine percent of patients have either in their serum or urine a monoclonal M 
protein and the rest have non-secretary type of myeloma. According to the data 
in the W e s t (Postgraduate hematology, Hoffbrand et al. 1989)，lgG (55.7%) is 
the most c o m m o n M protein, followed by lgA (26.7%), solely light chain (14.7%), 
lgD (1.5%) and lgM (0.2%). K-Iight chain is more c o m m o n than X,-Iight chain. 
Very rarely, biclonal M protein is seen. M a n y patients have low levels of other 
normal lgs. This immunoparesis increases the susceptibility of patients to 
infection, which is one of the leading causes of death a m o n g myeloma patients. 
1.2 The Problem 
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A s a result of the low mitotic yield and also often complex karyotypic 
changes, specific cytogenetic abnormality in M M has not been found (Dewald et 
al,1985; Barlogie et al,1989; Ferti et al, 1984; Gould et al, 1988). Unlike most 
other hematological malignancies, no consistent specific translocation or 
structural anomalies have been reported. This fact has hindered the guided 
approach of molecular genetic studies that are commonly employed in leukemias 
and m a y otherwise yield more relevant results in this malignancy. A normal 
karyotype w a s seen in 50-60% of M M (Riedel et al, 1992). However, this needs 
to be interpreted with great caution as it w a s observed by flow cytometry that a 
high frequency (>80%) of D N A aneuploidy actually existed (National Cancer 
Institute, Annual Cancer Statistics Review, 1992). Nowadays, results from 
fluorescence in-situ hybridization (FISH) studies have suggested that almost all 
M M patients are cytogenetically abnormal (Zandecki et al, 1996) 
O n the other hand, molecular genetic data of M M are not systematic. N o 
consistent oncogene or tumor suppressor gene abnormalities have been found 
in h u m a n myeloma while variable abnormalities of expression in c-myc, ras, Rb 
and p53 have been described, c-myc, bcl-1 and bcl-2 involved in inhibition of 
apoptosis are highly expressed but no gene rearrangements have been detected 
thus far (Van den Berghe et al, 1989; Durie et al, 1992; Barlogie et ai, 1995). 
Despite frequent increased c-myc and bcl-2 expression (Pettersson et al, 1992; 
Selvanayagam et al, 1988; O n g et al. 1995) and the rather frequent occurrence 
oft(11;14) (q13;q32) involving the bcl-^ (Pettersson et al, 1992; Ladanyi et al, 
3 
1992), structural rearrangements of these genes are rare (Niesvizky et al, 1993; 
Ladanyi et al, 1992). 
Essentially a disease of the elderly, M M has a peak incidence in 
individuals at 70 to 80 year of age. T h e age adjusted incidence rates in the 
Chinese of Hong Kong per 100,000 are 1.7 for m e n and 1.5 for w o m e n (Hong 
Kong Hospital Authority, Annual statistical report of Hong Kong, 1993)，which are 
2-3x lower than in the West. Data on the study of M M in Chinese are 
correspondingly fewer. Although the median age at diagnosis is 70 years, it is 
not u n c o m m o n for the disease to be diagnosed in m u c h younger patients (< 40 
y.o.). Moreover, there is a trend that younger patients (<30 y.o.) are also 
affected in recent years. Unfortunately, little improvement in the 5-year survival 
rates has been m a d e since the mid-1970s despite advances in prognostication 
and the use of multiagent chemotherapy. The slow progress in terms of 
treatment strategy compared to other hematological malignancies m a y be a 
reflection of our poor understanding of M M pathogenesis. T o date, this 
malignancy is still regarded as a uniformly fatal disease not curable by 
chemotherapy. Although hereditary factors, radiation exposure, agricultural 
exposure, and antigenic stimulation have all been implicated to s o m e extent, the 
etiology and pathogenesis of M M remain obscure. 
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2.1 Molecular genetics of multiple myeloma 
2.1.1 Cytogenetics 
The most frequent abnormalities described so far in multiple 
myeloma(MM) are listed in Table 1. A n abnormal karyotype is found in 
approximately 5 0 % of patients, while the use of FISH and D N A content of 
plasma cells demonstrates abnormalities in nearly 9 0 % of the M M patients. The 
abnormal karyotypes generally show numerous numeric and structural 
aberrations, and s o m e patients have multiple abnormal clones. However, 
although cytogenetic studies have been carried out in m a n y patients with 
different types of plasma cell disorders, it is clear that no single pattern occurs in 
M M (Zandecki, 1996). 
Most of the structural rearrangements identified so far have been those 
associated with B-cell neoplasms (Zandecki, 1996). 14q32 translocation is a 
non-random structural abnormality in M M , occurring in about 20-30% of cases 
with an abnormal karyotype. The most frequent 14q32 translocation is 
t(11;14)(q13;q32.3), occurring in about 10-25% cases with abnormal karyotypes 
(Zandecki, 1996) Many other translocations have also been reported, including 
t(8;14)(q24.1;q32.3). 
6 
t(14;18)(q32.3;q21.3) and t(6;14)(p21.1;q32.3) (Gould et al, 1988; Nishida 
et al, 1989a,b). 
Table 1. Main numeric and structural changes that have been 
reported in multiple myeloma. 
Numeric changes 
Gains: 9，3’ 19’ 15，11’ 7’ 5, 18’ 2 1 (trisomy or tetrasomy) 
Losses: 13*, X (females), 14, 8’ Y (monosomy or nullosomy) 
Structural changes Main associated changes 
14q+ (11;14)(q13;q32) 
(8;14)(q24;q32) 
(14;18)(q32;q21) 
(6;14)(p21;q32) 
16por16q (1;16)(p11;p11) 
(1;16)(q10;p10) 
1p or 1q (partial deletion, trisomy 1q) 
19q13or19p13 
6q 
17q 
2p12or 22q11 
7q 
(9;22)(q34;q11) 
* Loss of whole or part of chromosome 13. 
Adapted from Zandecki, 1996 
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6q abnormalities have been found in approximately 1 0 % of M M patients. 
This abnormality is associated with increased levels of osteoblast activating 
factor (OAF) and T N F production and m a y imply increased risk of osteolytic bony 
involvement (Gould et al, 1988). 
7q abnormalities are also relatively c o m m o n . Such deletions are 
associated with the expression of the multi-drug resistance ( M D R ) phenotype 
since this is the locus of the gene encoding for p glycoprotein, product of the 
mdr-1 gene. Over-expression of m e m b r a n e p glycoprotein m a y lead to activation 
of an ATP-dependent efflux p u m p which expels drugs from the cell (Dalton et al, 
1992). 
Structural abnormalities of c h r o m o s o m e 1 have been described in about 
40-50% of M M patients and abnormal karyotypes involving translocations, 
deletions, duplications and inversions (Zandecki et al, 1996) 
T w o structural aberrations, both involving 16p, were reported in M M . 
Flactif et al (1994) reported a t(1;16)(p11;p11) in two patients, and c h r o m o s o m e 
painting confirmed the abnormality as located at 16p11. 
Structural aberrations for other chromosomes have also been described. 
Those involving c h r o m o s o m e 19 have been reported by two studies (Taniwaki et 
al，1994; Lai et al, 1995). La.i. et al (1995) described 19q13 abnormality in 12.5% 
of patients with an abnormal karyotype. Taniwaki et al (1994) found that a 
breakpoint at 19p13.3 w a s recurrently involved in translocations of c h r o m o s o m e 
19. 
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Fluorescence in situ hybridization (FISH) has enabled detection of numeric 
chromosome changes in both interphase and metaphase cells using D N A 
probes directed against one part of a chromosome (Hasegeli Uner et al, 1994). 
FISH techniques can be performed on bone marrow smears, cytospins, and 
cytogenetic preparations (Lee et al, 1993; Flactif et al, 1995). By interphase 
FISH analysis using probes for 5 and 10 different chromosomes, respectively, 
two studies reported that at least one chromosome is trisomic in 9 6 % or 8 9 % of 
myeloma (Drach et al, 1995; Flactif et al, 1995). The significance of the numeric 
chromosomal abnormalities is unclear in M M ; they m a y be associated with 
tumor progression whereas structural aberrance m a y be more important in the 
origin of the clonal neoplastic disorder (Dewald & Jenkins, 1991). 
The low mitotic yield and complexity of karyotypic changes both have 
been a Hindrance to a directed approach to the study of oncogenes and 
suppressor genes (Zandecki, 1996). A number of genes recognized to be 
important in other B-cell malignancies were found to abnormal in M M namely, c-
myc, /)c/-1, bcl-2, M-ras, and H-ras. Abnormalities of Rb, p53 and other tumor 
suppressor genes were also described. Studies at the molecular level have 
revealed alterations in proto-oncogenes, tumor-suppressor genes, and most 
recently, cell-survival genes in patients with multiple myeloma. 
2. 2 Alterations of proto-oncogenes 
2. 2. 1 c-myc 
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The myc proto-oncogenes encode nuclear phosphoproteins involved in 
the control of cellular proliferation and differentiation (Feinman et al, 1997). The 
c-myc gene (on chromosome 8q24) plays a role in the pathogenesis of a number 
of B-cell malignancies (Varterasia, 1995). However, in myeloma, gross structural 
changes involving chromosome 8 are rarely seen (Varterasia, 1995). 
Deregulation of c-myc appears to participate in the pathogenesis of M M since 
high level of c-myc expression has been seen. The elevated c-myc expression 
might be caused by mutation in the 5'-untranslated region of the c-myc gene 
leading to a deregulated translational control of c-myc gene expression (Paulin et 
al, 1996). 
2. 2. 2 Ras 
The p21/ras signaling transduction pathway integrates a variety of growth 
and inhibitory signals that are critical for cellular proliferation and differentiation. 
In a recent study, a high incidence of ras mutations (49%), with N-ras being the 
most frequent, was detected in 160 newly diagnosed M M patients (Liu et al, 
1996). A significant correlation with tumor burden and survival was seen only in 
those patients harboring a K-ras mutation. 
2. 2. 3 BCI-2 and related proteins 
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Expression of bcl-2 is thought to play an important role in B-cell 
malignancies. In myeloma, the t(14;18) translocation, typical for follicular 
lymphoma which results in over-expression of bcl-2, occurs at low frequency (2-
3。/o) (Sawyer et al, 1995). However, over-expression of bcl-2 is seen in the 
majority of M M and M M cell lines (Ong et al, 1995; Pettersson et al, 1992; 
Ladanyi et al, 1992). Hypomethylation was proposed as a potential mechanism 
for the upregulation of the bcl-2 expression (Hanada et al, 1993). Over-
expression of bcl-2 in cancer cells can result in chemoresistance and blocks 
apoptosis (Hallek et al, 1998). 
2. 3 Alterations tumor-suppressor genes 
2. 3 .1 p53 gene mutations 
The p53 tumor-suppressor gene encodes a nuclear DNA-binding protein 
that is active in cell-cycle regulation (Varterasian, 1995). The p53 gene has m a n y 
effects on cell growth and differentiation and is often viewed as a gate-keeper to 
enter the cell cycle (Hallek et al, 1998).. 
PG3 mutations are very rare in M M , and appear to be a late event in the 
dis^se (Yasuga et al, 1995) • p53 mutations occur only in about 5 % of inactive 
M M (Portier et al, 1992). 
2. 3. 2 Retinoblastoma (Rb) gene 
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The retinoblastoma tumor suppressor gene product (pRb), a nuclear 
phospoprotein that suppresses the G1-S in the cell cycle, plays an important role 
in cell growth and differentiation. (Weinberg, 1995; Livingston et al, 1989; 
DeCaprio et al, 1989; A d a m s et al, 1996; Weinberg, 1991; Weinberg, 1993). 
pRb function is regulated by phosphorylation. Dephosphorylated p R b is active 
form and that prevents the cell to enter the S phase and hence induces the cell-
cycle arrest; in contrast, p R b is phosphorylated and hence inactivated by the 
cyclin dependent kinase (CDK) CDK4/6-cyclin D complex thereby promotes the 
entry of cells into S phase (Weinberg, 1995). Alterations of the Rb gene or 
abnormalities in p R b have been described in up to 7 0 % of M M patients and 8 0 % 
of MM-derived cell lines (Corradini et al, 1994; Dao et al, 1994; Juge-Morineau 
et al, 1995). By Southern blot or interphase FISH analysis, monoallelic deletion 
of Rb (or loss of one copy of chromosome 13) has been reported in about 5 0 % 
to 6 0 % of primary M M and cell lines respectively, independent of the disease 
stage. Bi-allelic deletion of Rb w a s found in 1 of 22 M M cell lines and in 1 of 10 
primary tumors (Corradini et al, 1994; D a o et al. 1994; Juge-Morineau et al, 
1995). The monoallelic lesions were not associated with the p R b expression, 
and no mutations or rearrangements of Rb have been described (Juge-Morineau 
et al, 1995). These findings suggest that a bi-alleilic loss of the Rb gene is 
infrequent in M M and thus inactivation of Rb appears to be only a rare oncogenic 
event in M M . Since p R b can suppress IL-6 (Santhanam et al, 1991) which is the 
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crucial growth factors of M M , the factors involves in the upstream control of the 
Rb function and cyclin D-Rb pathway still worth further investigation. 
2 . 3 . 3 p16 and p15 genes 
A major candidate for the c h r o m o s o m e 9p21 tumor suppressor gene is 
p16 ( K a m b et al, 1994; Nobori et al, 1994). Later on, another tumor suppressor 
gene p15 has been identified on 9p21 near the p16. Both p16 and p15 are the 
inhibitors of cyclin dependent kinases C D K 4 / 6 by competing with cyclin D for 
binding to C D K 4 / 6 and hence preventing the formation of CDK-cyclin D complex 
which can phosphorylate the p R b (Kato et al, 1993). Deletions or mutations in 
the p16 or p15 gene m a y affect the balance between functional p16/p15 and 
cydin D, resulting in abnormal cell cycling and growth. Mutations of p16 were 
described in m e l a n o m a cell lines ( K a m b et al, 1994; Nobori et al, 1994) and 
demonstrated in the germ line of several m e l a n o m a kindreds linked to 9p21 
(Hussussian et al, 1994; K a m b et al, 1994). Multiple small studies showed that 
no homozygous deletions or mutations of p16/p15 genes are involved in M M ( 
Quesnel et al, 1995; Hangaishi et al, 1996; O g a w a et al. 1995). 
Recently, inactivation of p16/p15 by an alternative mechanism, de novo 
methylation of 5'CpG island, has been demonstrated in m a n y tumors (Merlo et 
al，1995; H e r m a n et al, 1995; Gonzalez-Zulueta et al, 1995; Lo et al, 1996). 
Such a mechanism, which has been a focus of attention in the study of 
oncogenesis, has not been examined in M M . 
13 
Chapter 3 
DNA methylation and Cancers 
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3.1 Role of DNA methylation 
It is getting clear that D N A methylation, essential for normal embryonic 
development, plays an important role in carcinogenesis. Alterations in D N A 
methylation are very c o m m o n in cancer cells. Current interest in the role of 
methylation has focused on the potential of aberrant methylation in silencing 
tumor suppressor genes, a novel pathway on the development of progressive 
epigenetic inactivation. R a n d o m methylation errors resulting in the de novo 
methylation of C p G islands on the promoter region m a y contribute to the 
progressive inactivation of growth-inhibitory genes resulting in the clonal 
selection of cells with growth advantage. Promoters silenced by methylation can 
be reactivated by treatment with the demethylating agent 5-aza-2'deoxycytidine. 
This mechanism of gene inactivation in carcinogenesis has important clinical 
implications, since it is possible to reactivate these dormant genes using 
inhibitors of D N A methylation and potentially restore growth control of cells 
(Jones, 1996). 
3.2 CpG islands 
C p G islands are G + C rich regions that show a high frequency of C p G 
dinucleotides and usually unmethylated in normal somatic cells (Bird, 1986), 
except during X-chromosome inactivation (Singer-Sam et al, 1993), Alu and L1 
sequences (Liu and Schmid, 1993) and parental specific imprinting (Li et al, 
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1993). However, widespread methylation of the C p G islands was observed on 
autosomal genes during oncogenic transformation (Jones and Buckley, 1990; 
Laird and Jaenish, 1994). Many studies have demonstrated that aberrant 
hypermethylation is associated with inactivation of tumor suppressor genes. 
3.3 Abnormalities of DNA methylation in neoplasia 
D N A methylation changes are the most c o m m o n detectable abnormalities 
in human neoplasia (lssa et al, 1997). There are three major alterations in the 
methylation system being described: (1) widespread loss of D N A methylation 
from normally methylated sites; (2) increased total activity of the D N A 
methyltransferase (Mtase); and (3) regional increases in D N A methylation, often 
involving the C p G islands in the promoters of selected genes such as the tumor 
suppressor genes lssa et al, 1997). Each of these changes has potentially 
profound consequences for D N A function and structure, and the interplay 
between them m a y be particularly important for neoplastic progression (Baylin et 
al, 1998). 
3.3.1 DNA Hypomethylation in cancer 
The earliest alteration of D N A methylation to be described in h u m a n 
neoplasia w a s the loss of 5-methyl-cytosine (Feinberg et al, 1983). This 
demethylathylation process has been proposed to play a role in potential 
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activation of growth promoting genes such as oncogenes and hence possibly the 
induction of chromosomal instability (Jones and Buckley, 1990). The decreased 
D N A methylation has been described in s o m e oncogenes in h u m a n tumors, 
however, the demethylation is not always associated with reactivation at the 
gene expression level (Kochanek et al, 1991). 
3.3.2 DNA methyltransferase activity in cancer 
In addition to D N A hypomethylation, elevation in methylatransferase 
(Mtase) activity has also been observed in a variety of cancer cell lines and 
primary tumors (Kautiainen et al , 1986; lssa et al, 1993; Belinsky et al, 1996). 
Over-expression of Mtase m a y be important in pathogenesis of neoplasia since 
high level of Mtase activity results in a marked increase in overall D N A 
methylaltion which is accompanied by tumorigenic transformation in non-
tumorigenic line NIH-3T3 ( W u et al., 1993). Another study demonstrated that 
phenotype in a malignant cell line could be reverted by inhibition of Mtase activity 
(MacLeod and Szyf, 1995). Their results support the hypothesis that the D N A 
Mtase is actively involved in oncogenic transformation. All these observations 
are consistent with a role for increased Mtase levels in neoplasia (lssa et al, 
1997). 
3.4 Regional DNA hypermethylation in cancer 
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Work during past 10 years on D N A methylation suggests that the normally 
unmethylated C p G islands in the 5，regulatory regions of genes would be a prime 
target for aberrant hypermethylation in tumor cells and is the most profound 
association between altered D N A methylation and changes in gene expression 
in neoplasia (Baylin et al, 1998). Dense methylation within a 5' regulatory region 
has the potential to participate in chromatin events that result in transcriptional 
silencing of an involved gene. Examples of such genes include the two cell-cycle 
regulators p16 (Gonzalez-Zulueta et al, 1995) and p15 (Herman et al, 1996)，the 
von Hippel-Lindau gene (VHL) in s o m e renal carcinomas (Herman et al, 1994), 
the retinoblastoma gene Rb (Stirzaker et al, 1997)，the BRCA 1 (Dobrovic and 
Simpfendorfer, 1997) and the metastasis-suppressor gene-cadherin (Graff et al, 
1995). 
3.4.1 p16 and p15 genes in solid tumors 
The function and the role in cyclin D-Rb pathway of the two cell-cycle 
regulators p16 and p15 have been addressed previously (see Chapter 4 
Background of studies). In m a n y h u m a n cancers, the c o m m o n structural lesion 
of chromosome 9p21 is homozygous deletion of an region residing not only the 
Pl6 gene but also the nearby p15 gene (Jen et al, 1994; K a m b et al, 1994). 
However, studies of methylation patterns for the p15 and p16 genes in solid 
tumors have pointed to the more important role for the p16 gene (Baylin et al, 
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1998). A m o n g most solid tumor types studied, the frequency of hypermethylation 
of a 5’ C p G island of the p16 gene in primary tumors ranges from 20 to 6 7 % 
(Baylin et al, 1998). Only the p16 gene is frequently methylated when copies of 
both p16/p15 genes are retained in solid tumors (Herman et al, 1995，1996) with 
the exception that the p15 gene methylation is seen in lung cancer cell lines, and 
almost always with concomitant hypermethylation of the p16 gene (Herman et al, 
1996). Also, although point mutations are not frequent in the p16 gene, they do 
occur, but these have not been documented in the p15 gene (Herman et al, 
1995). 
3.4.2 The p16 and p15 genes in leukemia and other 
hematopoietic malignancies 
In tumors of hematopoietic origin, the patterns and mechanisms of 
inactivation for the p16 and p15 genes differ from those in solid tumors. The loss 
of p15 gene function is a dominant event in tumors derived from the 
hematopoietic cell system, and C p G island hypermethylation is by far the 
dominant mechanism involved (Baylin et al, 1998). Large studies of patients with 
both the adult and pediatric types of acute myelogenous leukemia (AML) showed 
hypermethylation on p15 in 8 6 % and 6 5 % respectively; (Herman et al, 1996; 
Herman et al, 1997). N o homozygous deletions or mutations of either the p15 or 
P16 genes have been involved, and the p16 gene is not concomitantly 
hypermethylated (Herman et al, 1996; Herman et al, 1997). The methylation 
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pattern seen for A M L also observed in adult acute lymphocytic leukemia (ALL) 
and pediatric B lineage subtype (Baylin et al, 1998). The high frequency of the 
involvement of p15 m a y be due to that normal hematopoietic stem cells are 
sensitive to TGF-p-mediated growth inhibition response (Baylin et al, 1998). 
For the lymphomas，p15 and p16 are rarely involved in low-grade non-
HodgkirVs lymphoma (NHL), and hypermethylation of the p16 gene alone was 
the only molecular event observed. In contrast, more than 8 0 % of high grade 
N H L have hypermethylation of the p16 gene (Baylin et al, 1998). In Burkitt's 
lymphoma, both the p15 and p16 gene are frequently simultaneously 
hypermethylated, and methylation of one gene or the other is a c o m m o n 
phenomenon in this neoplasm. 
Studies of the p16 and p15 genes on chronic myelogenous leukemia 
(CML) showed that no involvement of either the p16 or p15 genes by mutation or 
hypermethylation in any stage of C M L (Herman et al, 1997). 
3.4.3 Retinoblastoma gene 
The Rb gene was the first classic tumor suppressor gene in which C p G 
island hypermethylation was detected. The change has been noted in tumor 
D N A from about 1 0 % of patients with the non-genetic or sporadic form of 
retinoblastoma (Sakai et al, 1991). Although the Rb gene is commonly mutated 
in m a n y forms of h u m a n cancer, promoter region hypermethylation has been 
reported only in retinoblastomas (Baylin et al, 1998). 
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3_5 Mechanism underlying the DNA methylation changes 
In malignant cells, the 5’ CpG-island regions become methylated and the 
associated gene is transcriptional silencing (Counts and G o o d m a n , 1995). In the 
case of growth-regulatory genes such as the tumor-suppressor gene, this m a y 
result in clonal selection of cells with growth advantage. D N A methylation-
mediated transcriptional inhibition has thus been proposed as alternative 
pathway to the inactivation of tumor suppressor genes other than mutation and 
deletion (Jones,1996). 
A recent study by Chuang et al (1997) has proposed n e w pathways for 
the formation of methylation errors and mutations in cancer cells related to the 
proliferating cell nuclear antigen (PCNA) which is an auxiliary factor for D N A 
replication and repair. It w a s shown that the D N A methyltransferase (Mtase) 
methylates the newly replicated D N A by binding to the replication associated 
protein P C N A . The cell cycle regulator p 2 1 ^ F i can disrupt the D N A Mtase 
interaction which suggests that 21 m a y regulate methylation by blocking access 
of Mtase to P C N A . D N A Mtase and p21 m a y be linked in a regulatory pathway 
since the D N A Mtase is competing with p21 for P C N A and the extents of their 
expression are inversely related in both normal and S V 4 0 transformed cells 
(Chuang et al, 1997; W a g a et al, 1994). 
In a malignant cell, the loss of p21 would perturb a balance between the 
P21 and DNA-methyltransferase interaction with P C N A , which would allow for an 
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increase in methylation errors (Robertson and Jones, 1997). O n the other hand, 
the loss of p21 m a y also allow the methyltransferase access to sites of D N A 
damage, resulting either in a methylation error or in de novo methylation at a 
5_CpG site that is normally unmethylated. This type of random methylation error 
will then be potentially leading to the inactivation of the tumor suppressor genes 
(Robertson and Jones, 1997). 
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Chapter 4 
Background of study 
23 
4.1 Background of study 
Although m a n y studies have been conducted in the investigation of M M 
pathogenesis in recent years, there are still m a n y gaps of information with 
unresolved issues in this uniformly fatal cancer. The finding of a high incidence 
(>5Qo/o) of Rb deletions in M M by Dao et al in 1994 has started a new line of 
approach in the study of molecular genetics, providing insight for further research 
in this malignancy (Dao et al, 1994). The potential involvement of this classical 
tumor suppressor gene in M M pathogenesis m a y have major implications 
because 1. Rb plays a critical role in the control of cell cycle progression by 
suppressing cell growth at the G 1 phase. Loss of R b function would lead to 
cellular proliferation and transformation; and 2. More importantly, Rb gene 
product (pRb) suppresses the gene transcription and hence production of 
interleukin-6 (IL-6) (Santhanam et al, 1991)，which is a crucial myeloma growth 
factor that also prevents cell apoptosis (Lichernstein et al, 1995). Rb deletions 
m a y result in deregulation of IL-6 expression and hence inhibition of apoptosis 
and expansion of IL-6 dependent myeloma clone. However, later study by Juge-
Morineau et al demonstrated that despite the frequent Rb deletions (81% in 
h u m a n myeloma cell lines ( H M C L ) and 7 0 % in M M patients) being found in M M , 
a majority of the Rb deletion were hemizygous and not associated with the loss 
of expression of the pRb. Bi-allelic deletions with loss of p R b expression were 
rare (4.5% in H M C L and 1 0 % in M M patients). 
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As a negative regulator of cell cycle, Rb is subjected to the control of a 
broad array of cyclins and cyclin-dependent inhibitors (CDIs) that play critical 
roles in tumorigenesis by governing balance of cell growth, division, survival and 
death (Karp et al, 1995). As illustrated in Diagram 1’ p16 and p15 participate in 
the upstream regulation of Rb function by modulating the interaction of cyclin D 
and the cyclin-dependent kinase 4 (CDK4)/CDK6, the complexes of which can 
phosphorylate and hence inactivate the p R b (Kato et al, 1993). Phosphorylation 
of p R b and related G 1 to S phase transition is triggered by activation of cyclin D_ 
C D K 4 / C D K 6 complex (Hirama et al, 1995). As cyclin-dependent kinase 
inhibitors, p16 and p15 compete with cyclin D for binding to C D K 4 / C D K 6 , 
resulting in dephosphorylation (hence activation) of pRb and related G 1 growth 
arrest (Hirama et al, 1995; Serrano et al, 1993). 
Encoding respectively a 16-KD and 15-KD protein, p16 and p15, close 
neighbors both mapped to chromosome 9p21 region, are tumor suppressors in 
multiple h u m a n neoplasias (Okuda et aI, 1995; O g a w a et al, 1995; Quesnel et al, 
1995; Stranks et al, 1995; Merlo et al, 1995; Herman et al, 1995). The unique 
feature of p16 is that inactivation is mainly by homozygous deletions in m a n y 
primary tumors and co-deletion with p15 is c o m m o n (Ogawa et al, 1995; 
Quesnel et al, 1995). In addition, p15 is up-regulated by TGF-p, which is a 
potent growth suppressor of hematopoietic progenitors in the bone marrow 
environment where a majority of myeloma cells are accumulated. 
If Rb is not the major target gene in M M pathogenesis, as suggested by 
Pi"evious data of rare Rb inactivation and the associated loss of p R b expression, 
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abnormalities (e.g. p16 and p15) in the upstream control of Rb function deserve 
further investigation. It has been demonstrated that M M cells m a y show a very 
strong expression of pRb (Zukerberg et al, 1996) that is mostly in its 
phosphorylated (inactivated) form (Urashima et al, 1996). However, 
homozygous deletions or point mutations in the coding regions of p16 and p15 
were not observed in multiple small studies on M M (Ogawa et al, 1995; Quesnel 
et al, 1995; Hangaishi et al, 1996). 
Recently，de novo 5'CpG island hypermethylation has been found to be 
associated with transcriptional silencing ofp16/p15 in m a n y h u m a n cancers with 
and without previously observed homozygous deletions (Merlo et al, 1995; 
Herman et al, 1995; Gonzalez-Zulueta et al, 1995; Lo et al, 1996). These 
findings have more strongly affirmed p16 as the most commonly involved tumor 
suppressor gene in h u m a n neoplasias. It also adds more weight to the tumor 
suppressor role ofpt5which, in acute myeloid leukemia (AML), has been shown 
to be predominantly involved through this aberrant methylation (Okuda et al, 
1995). 
Thus far, studies on the methylation status of p16 and p15 genes in M M 
have not been reported. It would be important to examine whether these two 
g e n ^ could be inactivated by this alternative mechanism of gene inactivation in 
MM-hypermethylation. 
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4.2 Project objectives 
The current study aims to investigate whether the p16/p15 genes are 
inactivated by deletions, mutations or hypermethylation of the 5'CpG islands that 
m a y serve as an alternative mechanism of inactivation of these genes in M M . 
The relationship between the status of Rb and p16/p15 will also be examined by 
Southern blot analysis. Finally, a clinico-pathological correlation will be 
performed to evaluate the potential roles of p16/p15 in M M pathogenesis and 
presence of potential biological subtypes，which if found, m a y alter treatment 
strategy and outcome. 
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Chapter 5 
Materials and Methods 
^ 
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5. 1 Patient samples 
Bone marrow materials from twenty-four patients diagnosed of multiple 
myeloma in Prince of Wales Hospital, The Chinese University of Hong Kong, 
Shatin’ Hong Kong, between M a y 1995 to March 1996 were recruited for the 
study. The diagnosis and staging classification followed the criteria by Durie and 
Salman (1975)(Table 2). Morphologically, the multiple myelomas were classified 
into three histological subtypes, namely, a. mature (>80% of myeloma cells had 
mature cellular morphology), b. intermediate (mixture of mature and immature 
myeloma cells present, of which 50-80% had mature morphology) and c. blastic 
(>50o/o of myeloma cells were blastic with nudeolations and dissociation of 
nuclear and cytoplasmic maturation) through the assessment 0门 the May-
Grunwald-Giemsa stained bone marrow aspirate smears and H & E sections of 
marrow clot and trephine biopsies. 
认 
5. 2 Normal controls 
Twelve normal peripheral blood samples were obtained from the spouses 
of patients with thalassaemia traits as part of their premarital check. The 
spouses were healthy and with normal complete blood pictures. A bone marrow 
aspirate sample w a s obtained from a healthy marrow donor for allogeneic bone 
^arrow transplantation. 
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Table 2 Criteria for diagnosis of multiple myeloma 
Major criteria 
I. Plasmacytoma on tissue biopsy 
II. Bone marrow plasmacytosis with > 30 % plasma cells 
III. Mocodonal globulin spike on serum electrophoresis exceeding 3.5 g /dl for 
lgG peaks or 2.0 g for lgA 
peaks, > 1 .Og /24h of K or X light chain excretion on urine electrophoresis in 
the absence of amyloidosis 
Minor criteria 
a. Bone marrow plasmacytosis with 10 % to 30 % plasma cells 
b. Monoclonal globulin spike present, but less than the levels defined above 
c. Lytic bone lesions. 
d. Normal lgM < 50 m g , lgA < 100 m g , or lgG < 600 m g I dl 
Diagnosis will be confirmed when any of the following features are 
documented in symptomatic patients with clearly progressive disease. 
The diagnosis of myeloma requires a minimum of one major + one minor 
criterion of three minor criteria that must include a+b. 
1. I + b, I + c, I + d (I + a not sufficient) 
2. Il + b, ll + c, ll + d 
3. Ill + a, lll + c, lll + d 
4. a + b + c, a + b + d 
"Adapted from Durie and Salmon, 1975 
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5. 3 Storage of the samples 
Samples were stored in -70°C bone marrow aspirates and normal 
peripheral blood samples either preserved in E D T A or heparin 0°C freezer until 
ready for D N A extraction. 
5.4 Materials 
5. 4. 1 Chemicals 
Ultrapure d N T P set 2'-deoxynucleosides 5'-triphosphate : dATP, d C T P , 
d G T P and d T T P were purchased from Perkin Bmer/Cetus ( Norwalk, C T U S A ). 
Acrylamide, N'N' -methylenebisacrylamide solution (2%) and acrylamide : N,N'-
nriethylenebisacrylamide (29:1, 4 0 % ) were purchased from Amresco (Solon, 
Ohio,USA), A m m o n i u m persulfate, and T E M E D (N, N, N', N'-
tetramethylethylenediamine) were purchased from Pharmacia Biotech (Uppsala, 
Sweden). Urea (Ultra-pure), Tris-base, S D S ( Sodium dodecyl sulfate )’ E D T A 
(Ethylenediamine-Tetraacetic Acid), X-gal (5-bromo-4-chloro-3-indoyl-p-D-
galactopyranoside), IPTG (lsopropyl-p-thiogalactopyranoside), Agarose and 
Ampicillin were purchased from Sigma Chemical C o m p a n y (St. Louis, U S A ) . [ 
cc-32p]dCTP (3000 Ci/mmol) and [y-^^P]ATP (3000Ci/mmol) were purchased from 
A m e r s h a m Life Science (Amersham, U.K.). All other chemicals were purchased 
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from Sigma Chemical C o m p a n y (St. Louis, U S A ) if not specified. 
5. 4. 2 Primers 
Primers used in the research, including primers for p-globin gene primers 
and primers for sequencing listed in Table 3 were purchased from Oligos Etc. 
!nc.(USA) and Gilco/BRL Life Technology (Gaithersburg, MD,USA). 
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5. 4. 3 Enzymes: 
Restriction enzymes EcoRl，Eagl, Hindlll, Sacll and Smal were 
purchased from A m e r s h a m Life Science (Amersham, U.K.) and N e w England 
Biolabs (Beverly, M A , USA). Taq D N A polymerase w a s purchased from 
Gibco/BRL Life Technology (Gaithersbury, M D , USA). T4 polynucietide kinase 
was purchased from United State Biochemical ( Cleveland, O H , U S A ) . 
5. 5 Methods 
5. 5 .1 Cloning of p16 and p15 exon 1 probes for Southern analysis 
5. 5 . 1 . 1 PCR amplification of p16 and p15 exon 1 probes from normal 
blood DNA 
Amplification of p16 and p15 exon 1 D N A fragments from normal blood 
D N A was obtained by using the published primer sequences listed in Table 3. 
The P C R conditions used for the amplification were one cycle at 95°C (5 min); 
four cycles at 95°C (10 s) with annealing temperature (Tann)=64°C (10s) and 
72°C (10s); four cycles with Tann=62°C; four cycles with Tann=60°C; four cycles 
with Tann=58。C; thirty cycles with Tann=56。C; followed by final elongation at 72。C 
for 5 minutes. After 1 0 % polyacrylamide gel electrophoresis, the band 
containing the D N A fragment of interest was excised from the gel and transfer to 
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an eppendorf tube. Autoclaved double distilled water 50 |J was added, and the 
sample was incubated at 65。C for 6 hours. After spinning at high speed in a 
microcentrifuge, the elutant 2 i^l was collected for re-amplification of the D N A 
fragment with the corresponding sets of primers and using the s a m e conditions 
as described above. 
5. 5.1. 2. Recovery and purification of p16 and p15 exon 1 DNA 
fragments 
The re-amplified D N A fragment was again electrophoresed and the band 
interested was excised from agarose gel, then the D N A fragment was recovered 
and purified for later cloning or direct sequencing. 
Agarose gel (less than 250 m g ) containing the D N A band to be extracted 
was excised by using a clean razor blade. The slice was cut into several smaller 
pieces, minced and transferred to a 1.5 ml microcentrifuge tube. The D N A 
fragments were eluted at 37°C water bath over night. After spinning at high 
speed for 1 minute in a microcentrifuge, the supernatant was collected in a 
clean microcentrifuge tube. The eluted D N A was precipitated by adding 2.5X 
volume of absolute ethanol and one tenth volume of 3 M sodium acetate pH5.2 
with addition of 5^ il glycogen. The mixture w a s placed in -20°C for one hour. 
After high speed centrifugation (13000rpm/10min/4°C), the D N A pellet w a s 
washed once with 7 0 % ice cold ethanol, dried and resuspended into 20^il of T E 
buffer. A n aliquot of the D N A was quantitated and qualified by electrophoresis 
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on an 10 % polyacrylamide gel with ethidiun bromide staining, and the rest was 
stored at -20 °C until needed. 
5 . 5 . 1 . 3 Ligation 
The pCR-Script™ SK(+) cloning kit from stratagene (Stratagene, U S A ) 
was used to clone the P C R products of interest. Steps such as the ligation, 
transformation and plating were followed as described in manufacturer's 
direction with minor modification. 
For ligation, the ideal ratio of insert-to-vector D N A is 5:1 to 10:1. To a 
microcentrifuge tube, the following components were added in order: 1^1 of 
pCR-Script™ cloning vector (10 ng/^ il ); 1^ il of pCR-Script™ 10 x reaction 
buffer; 0.5^1 of 10 m M ATP; 2-4^il of recovered P C R product; V I of Srf\ 
restriction enzyme (5 ^ iL / ^ 1); 1^1 of T4 D N A ligase and distilled H2O to a final 
volume of 10 i^l. The mixture was incubated at room temperature for 1 hour, 
and then it was incubated at 65 °C for 10 minutes. The sample was stored on 
ice until transformation into Escherichia coli supercompetent cells. 
6. 6.1. 4 Transformation 
For transformation, the supercompetent cells (from The pCR-Script™ 
SK(+) cloning kit) were thawed on ice. 40^il of cells was aliquoted into a pre-
chj|led 15 ml Falcon 2059 polypropylene tube. 0.7)J of the p-mercaptoethanol 
37 
provided with this kit was added to the 40 d^ of bacteria to yield a final 
concentration of 25 m M . D N A of the ligation mixture 2|il was added to the 40^il 
of cells and swirled gently, then the reaction was placed on ice for 30 minutes. 
Heat shock was performed on the transformation mixture in a 42 °C water bath 
for 45 seconds, then it was placed on ice for 2 minutes. Preheated (42 °C ) S O C 
medium 2 ml was added into the transformation mixture and it was incubated at 
37 °C for 1 hour with shaking at 200 rpm. 
5. 5 . 1 . 5 Plating 
Aliquots of 50, 100，150 and 190 d^ of the transformation mixture were 
plated onto the LB-Ampicillin containing agar plates (50 ^ g/ml of Ampicillin) with 
X-gal (20^ il of 1 0 % (w/v) X-gal) and IPTG (20^1 of 0.2 M IPTG). Using a sterile 
spreader, the mixture was spread evenly on the surface of the plates and the 
agar plates were incubated inversely overnight at 37 °C . 
5. 5.1. 6 Screening of recombinant plasmid 
The cloned plasmid colonies were analyzed by restriction enzyme 
digestion, P C R and the D N A inserts were confirmed by D N A sequencing. 
5. 5. 1. 6. 1 Cultures of Transformants 
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Colonies of the transformants appeared on the agar plates were picked 
with a flame-sterilized inoculating loop and streaked directly on the Ampicillin LB 
agar plate to check for the presence of Ampicillin-resistance marker. After 
overnight incubation at 37。C，single-isolated colonies were inoculated 2 ml of 
fresh LB broth in a 15 ml Falcon 2057 tube and incubated at 37。C with good 
aeration (shaking at 200 rpm) for ovemight. 
5. 5.1. 6. 2 Minipreparation of plasmid DNA by standard protocol 
After overnight culture, 1.5 ml ovemight culture cells were pelleted by 
centrifugation (6,500 rpm/5 min/ RT) and then resuspensed in 100。of Solution I 
(50 m M glucose, 25 m M Tris-base pH7.9 and 10 m M E D T A ) then 200 ul of 
Solution II ( 0.2N N a O H , 1 % S D S ) was added and mixed by inverting the tube 
severaltimes.Solutionlll(3Mpotassiumacetate, 2 M glacialaceticacid) 150^1 
was added and mixed by inverting the tube and chilled on ice for 10 min. The 
supernatant was then transferred into a microfuge tube after centrifugation 
(13000rpm/10min/4。C). The supernatant was extracted by 500^il of 
phenol/chroloform/isoamyl alcohol (25:24:1)(v/v/v) for 1 minute by votexing. The 
aqueous (top) phase w a s transferred into a 1.5 ml eppendorf tube and of 
absolute ethanol w a s added to the aqueous phase and mixed by inversion for 
several times. The plasmid D N A was pelleted by centrifugation at 13000 rpm/4 
min/RT. The supernatant was decanted and the pellet w a s washed with 7 0 % ice 
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cold ethanol and lyophilized. Finally, the D N A was resuspended into 50^J of T E 
buffer and ready for further restriction analysis and P C R amplification. 
5. 6.1. 6. 3 Minipreparation of plasmid DNA by Magic Minipreps DNA 
purification system 
The plasmid D N A was purified by Magic Minipreps D N A Purification 
system (Promega Corporation, Madison, Wl, USA). 1.5 ml bacteria culture was 
transferred to a 1.5 ml eppendorf tube and pelleted by centrifuged at 6500 rpm 
for 5 minutes. The pellet was resuspended into 200^il of Cell Resuspension 
Solution and then mixed with 200|ul of Cell Lysis Solution by inverting the tube 
several times until the solution clear. The lysate was neutralized by 200^1 of 
Neutralization Solution and centrifuge at 13,000 rpm for 5 minutes. The cleared 
supernatant was decanted to a new microcentrifuge tube and 1ml of the Magic 
Minipreps D N A Purification Resin was added and mixed with the supernatant. 
The resin/DNA mix w a s pipetted into syringe barrel and passed through the 
Minicolumn by a vacuum . The Minicolumn w a s washed with Column W a s h 
Solution and dried by applying a vacuum and centrifugation (13,000 rpm / 20 
sec) to remove any residual Column W a s h Solution. The plasmid D N A retained 
in the Minicolumn was eluted by 50^1 T E buffer and the plasmid D N A w a s stored 
at _20°C for later analysis. The plasmid D N A prepared by this method w a s used 
for D N A sequencing. 
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5. 5.1. 6. 4 Screening of recombinants by restriction enzyme digestion 
After minipreparation of plasmid D N A , the plasmid D N A was digested by 
double restriction enzymes Hind\\\ and SacW which had the cutting sites on the 
vector in each side of the inserted D N A fragments. The restricted D N A was 
subjected to electrophoresis on 1 % agarose gel followed by staining with 
ethidium bromide and visualized under U V light. A n additional D N A fragment 
with the expected size indicated this clone contained the insert of the P C R 
product. The vector plasmid D N A restricted with Hind\\\ and BamH\ and the 
P C R product were used as references. X D_H/ncM fragments and ^X174 R F 
DNA/Haelll fragments were used as molecular weight markers. 
5. 5.1. 6. 5 Screening of recombinants by PCR 
Alternatively, the plasmid D N A obtained from candidate clones through 
the Minipreparation were subjected to P C R . Using the corresponding sets of 
primers in the first round of P C R and with the s a m e conditions, the plasmids 
D N A was amplified to determine if it contained the insert after agarose gel 
electrophoresis of P C R product. The presence of the right band indicated the 
clone containing the insert interested. 
At least four positive clones from each cases were analyzed and the 
plasmid D N A was subjected to further analysis by D N A sequencing. 
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5. 5. 1 • 7 Confirmation of cloned DNA by sequencing 
ATaq cycle-sequencing kit (United States Biochemical) was used to 
sequence p16 and p15 exon 1 fragments inserted in the pIasmid (pCR-Script™ 
SK(+) vector). The manufacture's directions were followed with minor 
modification. D N A amplification and sequencing reactions were carried out on 
all samples twice to eliminate errors due to possible contamination which might 
occur during the amplification reactions. 
5. 5.1. 7 .1 Primers used in sequencing 
For sequencing cloned D N A , primers for the T7 and T3 R N A polymerase 
promoters located on the vector in the up-stream or down-stream of the inserts 
were used as sequencing primers. If necessary, primers (the P C R amplification 
primes) located in the insert were also used as sequencing primers (Table 3). 
D N A sequencing for the cloned inserts was performed by using the ATaq cycle-
sequencing kit (United States Biochemical). 
5. 5.1. 7. 2 End-labeling sequencing primer 
For D N A sequencing, both the upstream or the downstream sequencing 
primers of the corresponding D N A fragment were labeled at their 5'-ends. The 
10 pmol of primer w a s labeled with 2.5 \^ [y-^^P] ATP(5000Ci/^l, Amersham) by 
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10 units of T4 polynucleotide kinase in a total volume of 10 i^l of kinase buffer, 
and incubated at 37 °C for 30 minutes. To stop the reaction, the tube was 
placed in a 70 °C water bath for 10 minutes and then it was placed on ice until 
ready for use. 
5. 5. 1. 7. 3 Cycle sequencing reactions 
Labeled primer and template were repeatedly cycled through alternating 
periods ofdenaturing, annealing, extension and termination. 
Four 0.5 ml microcentrifuge tubes were labeled as "A", "C", "G" or "T" for 
the respective termination, and 4^1 of the corresponding Termination Mix was 
aliquoted into the appropriately labeled tube. The tubes were placed at 4 °C 
until needed. 
For each D N A template to be sequenced, the following master mix were 
prepared containing D N A template (50^ig /^l ) 2^1; labeled primer 1^ il; reaction 
buffer 2^ il (260 m M Tris-HC, pH9.5, 65 m M M g C y ; diluted ATaq D N A 
Polymerase (1 unit / ^ l) 2^1; sterile distilled H2O 10^1 to a total volume 17^1. 
Then 3.5^1 of the master mix was aliquoted into each of the labeled tubes 
containing the termination mix. The evaporation of reaction mixture was also 
prevented by addition of a drop of mineral oil to each tube. The tubes were 
placed into a pre-heated ( 95 °C ) thermal cycler for 5 minutes and then followed 
the cycling program for 40 cycles: 95 °C for 30 seconds; 58 °C for 1 minute; 
72 °C for 30 seconds, and final elongation for 5 minutes. 
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After cycling reaction, 4|J of stop solution was added below the oil overlay 
to stop the reaction. Finally, 2 ^1 of the each sample was loaded onto the 
sequencing gel immediately after the sample was denatured at 95。C for 5 
minutes. The sequencing gel was electrophoresed under standard conditions. 
5. 5.1. 7. 4 Electrophoresis 
The sequencing system (Model S2, GILCO/BRL Life Technology) was 
used to separate the radioactive labeled D N A fragments by 6 % denaturing 
polyacrylamide gel containing 2 3 % urea. The sequencing gel was pre-run at 
constant 1700 volts for 30-60 minutes until 60° C was reached. The labeled 
D N A w a s denatured at 95° C for 5 minutes and chilled on ice before loading. 2 
^1 of each sequencing mixture was loaded into the adjacent well of the gel in the 
order of A, C, G and T. The electrophoresis was performed at constant 1700 
volts until the faster bromophenol blue dye reached the bottom of the gel. 
5. 5.1. 7. 5 Autoradiography 
After removing the gel from the electrophoresis apparatus, it w a s 
transferred carefully to a supporting sheet of filter paper (Whatman 3 M M No.1). 
Then it wa s covered with high-quality plastic wrap, and dried by using a vacuum 
gel dryer at 80° C for 1 h. Autoradiogram of the sequencing gel w a s obtained 
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after an overnight exposure of the dried gel to Kodak X - O M A T A R film ( Eastman 
Kodak Company) with double intensify screen. 
5. 5. 2 DNA Extraction and purification 
5. 5. 2 .1 DNA Extraction from bone marrow aspirate and peripheral blood 
Genomic D N A was extracted from bone marrow aspirate and peripheral 
blood by the phenol/chloroform method. The frozen marrow aspirate or blood 
samples were first thawed on room temperature then transferred to 15 ml Falcon 
2059 centrifuge tube. The cells were pelleted by centrifugation at 3200 rpm for 
10 minutes at room temperature, and the cells were washed three times with 1 X 
P B S until clear solution is achieved. The cell pellet w a s resuspended in 2 ml 
initial resuspension solution ( 0.35 M NaCI, 1.5 m M sodium citrate pH7.0, 0.5% 
S D S , 1 m M D T T ) and then proteinase K was added to a final concentration of 
100 i^g / ml and mixed gently by invasion of the tube. After incubation overnight 
at 55° C, the solution was cooled and the cellular D N A w a s extracted by mixing 
gently with 2 ml of ice-cold phenol /chloroform/ isoamyl alcohol (25 : 24 : 1) 
(v/v/v) reagent for 10 minutes. The mixture was then spun at 4000 rpm for 20 
minutes at room temperature. The upper aqueous phase w a s collected. D N A 
was precipitated by mixing with one-tenth volume of 3 M sodium acetate pH5.2, 
and two volumes of ice-cold absolute ethanol and placed on -20°C for 1 hour. 
The D N A precipitate was pelleted at 4000 rpm for 20 minutes, washed once with 
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7 0 % ethanol (-20¾), and finally dissolved in 2 ml of T E pH7.5. Trace of R N A 
present in the D N A sample was digested with 100^g / ml DNase-free RNase A 
for 1 hour at 37°C. The enzyme was inactivated by addition of the proteinase K 
at final concentration 100 ^ig/ml together with 0.5% S D S for 1 hour at 55°C. The 
D N A was again extracted with 2 ml phenol/chloroform/isoamyl alcohol (25:24:1) 
(v/v/v) reagent, precipitated with two times volume of absolute ethanol, and 
dissolved in 500^il T E pH7.5. After checking and measuring the quality and 
quantity of D N A , the D N A samples were stored at -20。C for later analysis. 
Special cares were taken to avoid cross-contamination among the samples. 
5. 5. 2. 2 Isolation of piasmid DNA from transformant cultures 
5. 6. 2. 2 .1 Cultures of Transformants 
Colonies of the transformants appeared on the agar plates were picked 
with a flame-sterilized inoculating loop and streaked directly on the Ampicillin LB 
agar plate to check for the presence of Ampicillin-resistance marker. After 
overnight incubation at 37。C, single-isolated colonies were inoculated 2 ml of 
fresh LB broth in a 15 ml tube and incubated at 37°C with good aeration for 2 to 
3 hr . Then 0.5 ml of the culture w a s inoculated into 200 ml of fresh LB broth 
containing 50 i^g /ml Ampicillin in a 500 ml conical flask. The culture w a s 
incubated at 37。C with shaking (200 rpm) for 6 hours. In order to improve the 
yield of plasmid D N A , chloramphenicol w a s added to 200^ig/ml, and the culture 
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was again incubated overnight with shaking (200 rpm) at 37。C. 
5. 5. 2. 2. 2 Extraction and purification of plasmid DNA (large scale 
preparation ) 
5. 5. 2. 2. 2 .1 Wizard Maxipres DNA purification system 
Wizard Maxipreps D N A purification system was used for rapid extraction 
and purification of plasmid D N A containing p16 and p15 exon 1 probes. 
Extraction and purification procedures were followed as described by the 
manufacturer. In brief, 200 ml of cultured cells was pelleted by centrifugation at 
3,000 rpm for 15 minutes at room temperature. The cell pellet was resuspended 
in 15 ml of Cell Resuspension Solution by pipetting up and down until no clumps 
were visible. 15 ml of Cell Lysis Solution was added to the suspension and 
mixed gently, but thoroughly, by stirring or inverting until the solution became 
clear and viscous (about 10 minutes). And then 15 ml of Neutralization Solution 
w a s added and mixed immediately by gently inverting the tube several times. 
The final mixture w a s centrifuged at 4,000 rpm for 15 minutes at 22-25°C in a 
room temperature rotor. The cleared supernatant was transferred to two 50 ml 
Falcon tubes by filtering through a filter paper (Whatman #1) and mixed with 0.5 
X volume of room temperature isopropanol. The mixture w a s again centrifuged at 
13,000 rpm for 15 minutes at 22-25°C in a room temperature rotor. The 
supernatant w a s discarded and the D N A pellet w a s resuspended in 2 ml of T E 
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buffer. 10 ml of Wizard Maxipreps D N A purification Resin was added to the D N A 
suspension above and mixed by swirling. Transfer the Resin/DNA mix into the 
Maxicolumn by applying a vacuum to pull the Resin/DNA into the Maxicolumn. 
The Maxicolumn w a s washed twice with 12 ml Column W a s h Solution and once 
with 5 ml of 8 0 % ethanol, dried by centrifugation at 2,000 rpm for 5 minutes. The 
plasmid D N A was eluted by applying 1.5 ml of preheated (65-70°C) T E buffer to 
the Maxicolumn and centrifuging at 2000 rpm for 5 minutes. The purified plasmid 
D N A was stored at -20°C for later use. 
5. 5. 2. 2. 2. 2 Standard protocol 
Cells of the choromphenicol-amplified culture were harvested by 
centrifugation at 4000 rpm for 20 minutes. Ten ml of lysis buffer ( 2 mg/ml 
lysozyme, 25 m M Tris-HCI pH 7.5, 10 m M E D T A pH 8.0 and 50 m M Glucose ) 
was added to resuspend the cells, followed by the addition of 20 ml of alkali-SDS 
solution( 1 % S D S and 0.2 N N a O H ). The solution was mixed and kept on ice 
for 5 minutes. Then 10 ml of 4 M sodium acetate ( pH 4.8 ) was added and 
incubated on ice for another 15 - 30 minutes. The mixture was mixed 
occasionally. After spinning at 12,000 rpm, at 4°C for 30 minutes, the 
supernatant w a s decanted into a clean 100 ml centrifuge tube. O n e volume of 
isopropanol and 1/10 volume of 3 M sodium( pH 4.8 ) acetate were added and 
the mixture was left on -20°C for 1 hour. The sample was again centrifuged at 
5000 rpm, for 10 minutes at 10°C. Then the supernatant w a s discarded, and the 
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pellet was resuspended in 5 ml of RNase buffer (10 m M Tris-HCI pH 7.4, 1 m M 
E D T A pH 8.0 and 10 |ug/ml RNase). After incubation at 37° C for 15 minutes, 
D N A was precipitated by adding 0.1 volume of 5 M NaCI and 10 ml of ethanol. 
The D N A pellet w a s then collected by centrifugation at 10,000 rpm, 2 minutes, 
and resuspended with 10 ml of RNase buffer. The D N A solution was clarified by 
centrifugation at 5,000 rpm for 10 minutes. The soluble plasmid D N A was 
extracted with equal volume phenol/chloroform/ isoamyl alcohol solution, 
precipitated with ethanol, and dissolved in T E pH7.5. buffer. The quantity and 
quality of the plasmid D N A were determined spectrophotometrically and the 
D N A was stored at -20。C for later use. 
5. 5. 2. 3 Checking of the quality and quantity of plasmid DNA 
The quality of the extracted D N A w a s analyzed by gel electrophoresis 
through a 0.3% agarose gel poured on a 1 % agarose support (the plasmid D N A 
was analyzed on 1 % agarose gel). 
The yield and purity of the D N A were determined by measuring the 
absorbance of the diluted D N A sample at 260 n m , 2 8 0 n m and 330nm using a 
Phamacia spectrophotometer. 
Purity Check: The ratio of (A260-A330)/ (A280-A330) =1.8 to 2.0 is the a 
acceptable parameter for D N A . 
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The ratio below this range indicates small amount of protein remaining in 
the sample. Ratio above this range represents the presence of R N A remaining in 
the samples. 
D N A concentration (^g / ml): D N A conc. = (A260-A330) x D F x 50 
where A260, A280 and A330 are absorbance at respectively 260 n m , 280 n m 
and 330 nm; and D F is the dilution factor. O n e unit absorbance at 260 n m equals 
50 i^g / ml D N A . 
5. 5. 3 Detection of hypermethlation by Southern blot analysis 
5. 5. 3. 1 Restriction enzyme digestion 
For Southern-blot analysis, each 5^g D N A extracted from bone marrow 
aspirate and peripheral blood w a s first digested with 30 units of methylation-
sensitive restriction enzyme Sacll, Eag\ or Smal separately at 37°C overnight 
(30。C for Smal) according to the recommendations of the suppliers. The 
restricted D N A w a s ethanol precipitated . After centrifugation, washing and 
drying, the resulting pellet was dissolved in T E buffer and further digested with 
30 units EcoRl or Hind\\\ at 37。C overnight. For reference, D N A from an 
unmethylated normal blood restricted with EcoRl or HincM alone were used as 
positive control for the methylation, and the D N A restricted with EcoR、or HindlW 
plus one of the methylation sensitive enzymes (Eag\, Sacll and Smal) w a s used 
as negative control for the detection of p16 and p15 methylation in Southern 
analysis. All twenty-four M M D N A were restricted with EcoRl or HindlW plus one 
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of the methylation sensitive enzymes (Eag\, SacW and Sma\). 
6. 5. 3. 2 Agarose gel electrophoresis 
After addition of loading dye, the D N A samples were fractionated by gel 
electrophoresis for 8 hours at 50 V using 1 % agarose gel in 1X T B E buffer. 
Molecular size marker consisted of H/ncflll-digested bacteriophage X D N A 
fragments was used, ihe gel was stained with ethidium bromide (0.1|ig / ml) for 
15 minutes and then visualized and photographed under U V light. 
5. 5. 3. 3 Southern transfer 
The gel was denatured in denaturation solution (1.5M NaCI, 0.5M N a O H ) 
for 45 minutes with gently shaking and neutralized by neutralization solution (3M 
NaCI, 0.5M Tris pH7.0) for another 45 minutes. The D N A was transferred to 
Hybon+ Nylon membranes (Amersham Corp. Hong Kong) by capillary action 
overnight. 
5. 5. 3. 4 Membrane fixation 
51 
5. 5. 3. 4 .1 UV cross-linking 
The membrane was allowed to air dry for an hour or dry at 80。C for 10 minutes 
and wrapped with Saran W r a p and then placed DNA-side down on a U V 
transilluminator for 2 minutes exposure. 
5. 5. 3. 4. 2 Alkali fixation 
The membrane w a s placed D N A side up on a pad of absorbent filter 
paper (Whatman No.1) 2-3 pieces thick soaked in 0.4M N a O H . After 20 minutes 
soaking, the membrane was rinsed by immersion in 5 x S S C or 5 x S S P E with 
gentle agitation for 1 minute. The membrane was sealed into a plastic 
hybridization bag (GILCO/BRL Life Technology) and ready for the hybridization 
step. 
5. 5. 3. 5 Recovery and purification of p16 and p15 exon 1 probe from 
plasmid 
The P C R generated p16 and p15 exon 1 probes were released from the 
cloning vector pCR-Script™ SK(+) by digestion with the restriction endonuclease 
SacW and HindlW under the conditions recommended by the manufacturer. 
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Typically, in a reaction volume of 200 ^1 , 200^ig of plasmid D N A w a s mixed 
with 200 units of restriction enzyme in 1X reaction buffer. The reaction mixture 
w a s incubated at 37°C overnight 
The restricted D N A w a s mixed with loading buffer consisting of glycerol, 
xylene cyanol FF and bromophenol blue loaded into the wells of a 1 % agarose 
gel containing 0.1 i^g / ml ethidium bromide. The electrophoresis w a s performed 
at 50 volts for 3 hours in 1X T B E in a horizontal gel electrophoresis system 
(Gilco/BRL Life Technology ). The Hind III digested 入-DNA marker w a s also run 
on the s a m e agarose gel parallel with the D N A samples. The electrophoretic 
pattern w a s visualized under U V illumination (UVP Transilluminator Benchtop, 
U V P Inc. Ultra-violet Products, Inc.), and EcoRl by a Polariod D S 3 4 direct screen 
instant camera using Polaroid 667 film (ASA 3000). The D N A band of interest 
w a s cut out with a sharp scalpel, minced and then transferred to 1.5 ml 
eppendrof tube with 0.5 ml T E buffer. The D N A probes were eluted out of the 
gel onto T E buffer by incubation in 37。C water bath overnight. After spinning at 
high speed for 1 minute in a microcentrifuge to pellet the pieces of agarose gel, 
the supernatant w a s collected in a clean microcentrifuge tube. The eluted D N A 
probes were concentrated by precipitation with one tenth volume of 3 M sodium 
acetate (pH 5.2) and 2 X volume of absolute ethanol with addition of 5 d^ of 
glycogen. The mixture w a s placed at -20。C for one hour. The identity and semi-
quantity of an aliquot of the D N A probes were confirmed and estimated by gel 
electrophoresis through an 10 % polyacrylamide mini-gel (Gilco/BRL Life 
Technology). The D N A fragments were then stored at -20。C. 
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5. 5. 3. 6 Probe labeling 
The p16 and p15 exon 1 fragments isolated from plasmid were labeled 
by rediprime D N A labeling system (Amersham Life Science). The D N A 
fragments to be labeled were diluted to 25 ng in 45^il of T E buffer (10 m M Tris-
HCI pH 8.0, 1 m M E D T A ) and denatured by heating to 95-100°C for 5 minutes in 
a boiling water bath. The denatured D N A was added to the labeling mix and 
reconstituted the mix by gently flicking the tube until the blue color was even 
distributed. Then 5 d^ of Redivue [a- ^^P] d C T P (3000Ci/mmol; Amersham Life 
Science) was mixed with reaction mixture and incubated at 37。C for 10 minutes 
and followed by adding 5|il of 0.2M E D T A to stop the reaction. The labeled 
probes were denatured by heating to 95-100。C for 5 minutes, then chilling on ice 
for later hybridization step. 
5. 5. 3. 7 Purification of radioactive labeled DNA probes by spun-column 
In order to minimize the degree of non-specific binding during the 
hybridization, the un-incorporated [a-^^P] d C T P was removed together with the 
unlabelled deoxynucleotides in the rediprime enzyme / buffer mixture. 
For the preparation of Spun-column, a 1.0 ml syringe (Japan Medical 
Supply Co., LTD) w a s plugged with a small piece of siliconized glass wool and 
then placed in an inserted. Equilibrated Sephadex G 5 0 ( Pharmacia A B 
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Molecular Biology) in S T E was allowed to fill the syringe and then it was packed 
down by centrifugation at 3500 rpm for 4 minutes. The syringe was re-filled with 
Sephadex G 5 0 and centrifugation were repeated until the column was packed to 
a volume of 1 ml and then the column was washed with 0.1 ml of S T E buffer 3 
times. After washing, 100|J of radioactive labeled D N A was applied onto the 
column. The effluent containing purified radioactive labeled D N A probes (100^il) 
was collected in a fresh decapped 1.5 ml eppendorf tube by centrifugation at 
3500 rpm for 4 minutes as above. 
5. 5. 3. 8 Southern hybridization 
Southern hybridization was performed in Rapid-hyb buffer (Amersham 
Life Science). The membrane w a s prehybridized with pre-warm rapid 
hybridization buffer at 65。C with shaking for at least 30 minutes. The labeled and 
purified D N A probe plus herring sperm D N A (100^ig/ml of buffer) was denatured 
at 95-100X for 10 minutes. A sufficient amount of labeled probe about 5 x 10® 
c p m / ml buffer of labeled probe was added to the hybridization buffer and the 
hybridization was carried out at 65。C with shaking for 2.5 hours. 
5. 5. 3. 9 Post hybridization wash 
After hybridization, the membrane was washed twice at room 
temperature for 10 minutes in 2 x S S C / 0.1% S D S , twice at 65。C for 10 minutes 
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in 1 X S S C / 0.1% S D S followed by three times at 65°C for 15 minutes washes in 
0.1 X S S C / 0.1% S D S with shaking. 
5. 5. 3.10 Autoradiography 
The membranes were wrapped in SaranWrap and exposed to Kodak X-
〇 M A T A R film (Eastman Kodar Company, Rochester, NY) in light-tight 
cassettes with two intensifying screens at -70°C for 1-5 days. 
5. 5. 4 Polymerase Chain Reaction-Single Strand Conformational 
polymorphism Analysis (PCR-SSCP) 
In P C R - S S C P analysis, the target sequence in genomic D N A was 
simultaneously amplified and labeled by using radioactive labeled primers. The 
amplified product was then denatured to a single-stranded form and subjected to 
non-denaturing polyacrylamide gel electrophoresis. Bands of the single-
stranded D N A at different positions in the autoradiogram indicate the presence 
of mutations. 
5. 5. 4 .1 5，- end radioactive labeling of primer 
In the presence study, 5'-end labeling kit (Amersham) was employed to 
radioactively labeled primers with [y-^^P] A T P ( 3000Ci/mmol) (Amersham) 
A pair of upstream and downstream primers ( 5 pmol each ) flanking each 
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exon of p16 and p15 was phophorylated with 5^ il of [y-^^P] A T P by 10 units of 
T4 polynucleotide kinase in a total volume of 10^1 phosphorylation reaction 
buffer incubated at 37。C for 30 minutes. These amount of radioactive labeled 
primers was enough for amplifications of target sequences in 40 D N A samples. 
5. 5. 4. 2 Amplification of target sequence by PCR 
The Taq D N A Polymerase (GILCO/BRL Life Technology) was used in 
this study for in vitro amplification of target sequence. 
The radioactive labeled primers solution was diluted with 105 ^1 of 
autoclaved double distilled water. In the P C R reaction mixture for 40 D N A 
samples，20 ^1 of 10X P C R buffer and 5^ il of 2.5 m M deoxyribonucleotide 
triphosphates (dNTP) mixture was added. After addition of 5 units of Taq D N A 
polymerase, 4jul of this P C R reaction mixture was aliquoted to forty 0.5 ml thin 
wall P C R tubes containing 1jJ (about 100 ng) of genomic D N A sample as D N A 
template in each tube and then a drop of mineral oil was added to prevent the 
evaporation. The P C R was carried out in a D N A Thermal Cycler (Perkin-Elmer 
Cetus) under the following conditions: the template D N A was first denatured by 
incubation for 5 minutes at 95。C followed by 40 cycles of P C R ( 1 min incubation 
at 60。C for annealing, 30 seconds at 72°C for polymerization and 30 seconds at 
94°C for denaturation). 
5. 5. 4. 3 Non-denaturing Polyacrylamid Gel Electrophoresis 
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The non-denaturing conditions, single-stranded D N A has a folded 
structure that is determined by intramolecular interactions in the nuleotide 
sequence. Different size and shape as well as its surface charge density of this 
particle caused different mobility in the non-denaturing polyacrylamide gel 
electrophoresis (Model S2, BRL). 
Before electrophoresis, the 5|ul of P C R product was mixed with 45^J of 
loading buffer and denatured by heating at 95。C for 10 minutes and chilling on 
ice. 2|ul of the denatured sample was loaded on a 40 c m polyacrylamide 
(BRL)(49:1, acrylamide: N,N'-methylene bisacrylamide)/0.5X T B E gel with the 
combinations of 8 % or 6 % polyacrylamide gel with or without 5 % glycerol added. 
The gel was run at two different conditions: 4。C/30 watts/4 hrs or 6 hrs in 
0.5XTBE buffer and RT/1.5 watts/18hrs in 0.5XTBE buffer. 
Finally, the gel was transferred onto W h a t m a n 3 M M No.1 paper and dried 
up using gel dryer (Model 583, G E L D R Y E R , BIO-RAD). Autoradiography was 
performed using an intensifying screen and an exposure of 12-48 hours at room 
temperature. 
5. 5. 4. 4 Direct DNA sequencing of PCR product for mutation 
Abnormal band with different mobility shift compared with the 
normal controls (normal blood and placental D N A ) were excised from the dried 
gel, placed in 50|J of autoclaved double distilled water, and incubated at 65。C for 
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6 hours. Supposingly, only P C R products from the mutated allele can be 
obtained. After centrifugation at 16,000 rpm for 10 minutes (Micro Centaur 
MSE), 10)J of supernatant w a s collected for re-amplification of this eluted D N A 
with the corresponding sets of primers using the s a m e conditions as described 
above in a total volume of 100 ^l. Following 6 % polyacrylamide (29:1, 
acrylamide: N,N'- methylenebisacrylamide)/1 X T B E gel electrophoresis (Model 
V16-2, Gilco/BRL), the slice of the gel with re-amplified P C R product w a s cut, 
minced and soaked in 500 i^l of T E buffer pH7.5 overnight at 37。C to release the 
D N A from the gel. In order to prevent contamination of the gel in the D N A 
sequencing reaction, the supernatant w a s collected for D N A extraction by 
phenol/chloroform method after spinning down all the minced gel. The re-
amplified P C R product w a s then precipitated by 2 volume of absolute ethanol at 
-20。C. The D N A pellet w a s dissolved in 20^1 of autoclaved double distilled 
water. This purified D N A w a s ready to be used for direct D N A sequencing using 
ATaqTM Cycle-Sequencing Kit (United State Biochemical). 
For direct sequencing, either upstream or down stream sequencing primer 
of the corresponding exon of the p16 and p15 w a s radioactive labeled by 5'-end 
labeling kit as above. The primers used for sequencing were the s a m e primers 
for P C R - S S C P analysis and listed in Table 3. The labeled primer w a s diluted 
one fold by autoclaved double distilled water before addition to sequencing 
reaction mixture. 
In the cocktail of D N A sequencing reaction mixture, 1|J of radioactive 
labeled primer w a s mixed with 2^J of re-amplified P C R product as template D N A , 
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2^ il of reaction buffer and 2|J of ATaq version 2.0 polymerase in total volume of 
17^ il. Then 3.5^1 of this cocktail was aliquoted to 4 termination tubes labeled 
with "A", "G", "C", and "T". Each tube contained 4^1 of one of the Termination 
Mix. For example, the "G" labeled termination tube was filled with 4|^ l of d d G T P 
Termination Mix. The evaporation of reaction mixture was also prevented by 
addition of a drop of mineral oil to each tube. The termination reactions carried 
out in a D N A Thermal Cycler using the sample condition for P C R - S S C P 
analysis. 
The addition of 4^1 of stop solution was followed to stop the termination 
reaction. Finally, the sample was boiled for 10 minutes and 2^ il of it was 
immediately loaded on the 8 % sequencing gel which was pre-run at 1700 volts 
for 30-60 minutes until 60。C was reached. After electrophoresis at 1700 volts for 
2 hours, the sequencing gel was blotted on to W h a t m a n 3 M M No.1 paper, dried 
in gel dryer and exposed to Kodak A R X-ray film (Eastman ) at room temperature 
for 12-48 hours with an intensifying screen. 
5. 5. 5 Prevention of overall contamination in PCR 
P C R is capable of amplifying a single copy of target D N A . Therefore, a 
major concern about this methodology is its susceptibility to contamination from 
other genomic D N A during preparation of samples or P C R reactions. 
Contamination m a y occur by three ways: sample to sample carry over; carry over 
of amplified D N A from previous P C R ; and contamination from sample or product 
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to PCR-reagents. To minimize potential errors due to carry over several 
procedures can be adopted. These include the physical separation of pre- and 
post-PCR procedures and performing the procedure in a laminar flow hood to 
reduce contaminating D N A by aerosols and to irradiation. 
Reagents were aliquoted and stored in an area free from amplified D N A . 
By labeling each lot and recording the usage of reagents, it was possible to track 
down contamination. Positive displace pipettes or filtered tips were able to 
reduce contamination from pipettes to samples. Precautions in the handling of all 
stages from sample collection, preparation, and extraction helped prevent cross-
contamination. These include the frequent changing of gloves, minimizing the 
handling of samples, the addition of non -sample reagents prior to the addition of 
D N A sample, frequent cleaning of equipment and work area to remove nucleic 
acid, and also care to reduce the production of aerosols. Separate rooms for 
pre- and post -amplification procedures. 
Aerosols are particularly important sources of contamination as particles 
can be as large as 20 ^im in diameter (4x10_V) and m a y carry 2.4x10^ copies of 
an amplified sequence. Appropriate controls were included in each batch of P C R 
and if any contamination w a s detected, results were repeated after de-
cont3min3tion. 
H u m a n placenta tissues as a negative control sample w a s subjected to 
the s a m e extraction and purification procedures as the multiple myeloma 
samples. For every sample preparation and extraction series, at least as m a n y 
negative control samples were included as primer pairs used. 
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For the detection of infectious agents, it was always necessary to check 
the patients sample for the presence of amplifiable D N A . This was done with 
primers that amplify a human p-globin sequence to check extracted D N A 
integrity. If the a sample can not be amplified by p-globin primers, the sample 
will be excluded for experiment. 
5. 5. 6 Sensitivity, specificity controls. 
To assess the specificity of each primer set, the amplified P C R 
products obtained from patient's D N A and normal blood D N A were analyzed 
by D N A sequencing. 
In addition, a negative control (buffer without sample) was included in 
every run. Results were considered valid only if they were consistent in at least 
two tests on samples derived from two independent extraction, and twelve 
normal bloods and one normal bone marrow aspirate were used as negative 
controls. 
Primers for h u m a n p-globin gene was also used as an internal control to 
test the quality of the purified cellular D N A for P C R . P C R of the p-globin 
gene, a product a of 268 bp, w a s used to assess the quality and the internal 
control of the P C R reaction. Amplification parameters were as follows : Aliquots 
(1-10^1) of prepared samples are amplified separately with primer pairs 
PC04/GH201. Each20|J reactionshouldcontain 50 ng of sample D N A ; 1 ^ M 
of each primer; 200 ^iM of each d N T P (dATP, d G T P , d C T P , dTTP); 1 units Taq 
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D N A polymerase (Gilco/BRL Life Technology) 1.5 m M MgCI2, and in 1X P C R 
buffer. Cycling parameters were 1 minutes at 95。C, 1 minutes at 56°C and 2 
minutes at 72°C for 35 cycles, followed by an additional 5 minutes extension at 
72°C on D N A thermal cycler (Perkin Elmer/Cetus). 
Aliquots of P C R amplified D N A were resolved on 1 0 % polyacrylamide gel, 
stained with ethidium bromide, and photographed under U V light. The results 
gave a indication of the quality of D N A . 
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Chapter 6 
Results 
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6.1 Patient characteristics 
6.1. 1 General patient characteristics 
A total of twenty-four M M patients were studied. All except one (No. 7) 
were Chinese. Table 4 shows the clinical and laboratory profile of the 24 M M 
patients. Male-to-female ratio was 1.4:1 with the median age at 58.6 and range 
from 25 to 81 years old. It is noteworthy that one patient (No.20) was diagnosed 
at 25 years of age, which is extremely unusual for M M . The median follow-up 
duration was 24 months from the first consultation at P W H to the time of data 
analysis. Eight died and fifteen patients were alive at the time of writing. O n e 
patient (No.17) w a s lost to follow-up. 
Our M M patients represent a group of patients with relatively advanced 
stage of the disease. Eighteen of them were at stage 丨11 disease and five at 
stage II and only one at stage I. Seventeen cases were analyzed on pre-treated 
samples. 
6.1.2 Clinical and laboratory features 
The diagnosis of M M w a s verified in each case with reference to the 
criteria from Durie and Salmon (2 and 4). Paraproteins fulfilling the major criteria 
by Durie were present in nineteen patients, sixteen of which in the serum and 
three in the urine. All except one (No. 5) patients had more than 3 0 % of 
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three in the urine. All except one (No. 5) patients had more than 3 0 % of 
myeloma cells in the bone marrow. Nineteen patients showed osteolytic bone 
lesions (Table 5A). Twenty-two patients had immunoparesis by protein 
electrophoresis. Three patients developed plasmacytomas as part of the 
myelomatosis process, one from the lgG isotype and two from the light chain 
disease (Table 4). Nine patients had renal failures although none showed 
hypercalcamia (Table 5A). Twenty-one patients had low albumins. Myeloma 
cells were identified through morphological assessment. They accounted for 25-
1 0 0 % of total nucleated cells present in the bone marrow. The complete blood 
counts showed a m e a n hemoglobin of 9.6 g/dL (range, 6.9-11.9), white blood 
count 4.4x10^/L (range, 2.9-7.1) and platelet count 161x10^/L (range, 52-432) 
(Table 5A). 
The immunoglobulin isotypic profile showed that thirteen patients were of 
lgG, seven lgA, one lgD and three light chain disease (Table 5B). Table 5 C 
shows the histological subtypes of our M M patients. Seven cases were 
classified as mature (Fig. 1A-B), nine as intermediate (Fig. 1C-D), seven as 
blastic (Fig. 1E-F) M M which also included one patient with anaplastic features 
(Fig. 1G-H). O n e patient showed atypical monocytoid myeloma cells. 
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Table 5A Clinical and laboratory features 
Lytic lesions 79% ( 19/24 ) 
lmmunoparesis 92% { 22/24 ) 
Plasmacytomas 13% (3/24) 
Renal failure 38% ( 9/24 ) 
Hypercalcaemia 0% ( 0/24 ) 
Hypoalbuminaemia 88% ( 21/24 ) 
o/oBMPC 25-100% 
Hb(g/dL) 6.9 — 11.9(9.0±1.41) 
W B C ( X 10®/L ) 2 .9 一 9 .6 ( 5 .4 土 1 .85 ) 
PLT(x1Q9/L) 5 2 - 4 3 2 ( 2 0 8 i 1 1 3 ) 
Paraprotein 79% ( 67% S and 12% U) 
B M P C : Bone marrow plasma cell 
H b : Hemoglobin 
W B C : White blood cell 
P L T : Platelet 
S : Serum 
U : Urine 
77 
Table 5B Profile of immunoglobulin isotvpes 
Our Patients (N=24) Others* 
lgG 54% 56% 
lgA 29% 26% 
lgD 4% 1.5% 
LC 13% 15% 
lgM 0% 0.2% 
NS 0% 1.1% 
* Data from Western literature (Galton D A G : Myelomatosis. Postgraduate 
Hematology, Butterworth Heinemann, p. 474, 1989) 
Table 5C Histological subtypes 
Histological Subtypes MM patients (N=23) 
Mature 30% 
Intermediate 39% 
Blastic ^  
* O n e case excluded as it is typed as classified monocytoid 
myeloma 
78 
6. 2 Southern blot analysis of p16lp15 and Rb 
6. 2 .1 Absence of deletions or hypermethylation 
in normal controls 
The presence of 5'CpG islands located around the transcription start sites 
of both p16 and p15 have been described previously (Herman et al, 1996; 
Gonzalez-Zulueta et al, 1995). Restriction of genomic D N A from bone marrow 
aspirates of our twenty four M M patients with the flanking enzyme EcoR\/Hind\\\, 
plus a methylation-sensitive enzyme {SacW, Eag\ or Smal), on Southern 
hybridization with the exon 1 probes of p16 and p15 provided information on 
deletion and the methylation status of the 5'CpG islands of these genes (Merlo et 
al, 1995; Herman et al, 1996). As is typical of 5'CpG island in normal cell, twelve 
normal peripheral blood and one normal bone marrow aspirate samples tested 
showed no deletions or hypermethylation of the p16 (Fig. 2A) and p15 genes 
(data for p15 not shown). 
6.2.2. Absence of homozygous deletions or mutations 
in p16/p15 and Rb among all MM patients 
By Southern blot analysis, none of our M M patients had homozygous 
deletions of either p16 or p15 (Fig. 2B-D). The status of Rb was examined by 
two Rb c D N A probes (3.8 kb and 1.9 kb). N o homozygous deletions or gene 
rearrangements were observed in our twenty-four M M patients (Table 6). 
The exons 1，2 & 3 for p16 and exons 1 & 2 for p15 were examined using PCR-
S S C P and D N A sequence analysis. N o mutations were identified in the coding 
79 
sequences of these genes (Table 6). All findings above were consistent with that 
in the literature. 
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6. 2. 3 Hypermethylation of p16 
The restriction m a p of p16 is as shown in Figure 3A. With 5'CpG island 
hypermethylation of p16, the digestion by the methylation-sensitive enzymes 
would be protected and the 4.3 kb EcoRl flanking fragment would result. W h e n 
the gene is unmethylated, digestion by the methylation-sensitive enzymes would 
yield smaller fragments. The expected sizes of these smaller fragments with 
different methylation-sensitive enzymes are depicted (Fig. 3A). The three 
methylation-sensitive enzymes (SacW, Eag\ or Sma\) have different methylation-
sensitive restriction sites with respect to gene sequences and hence locations 
(Fig, 3A). In the twenty-four patients analyzed, eight patients (No. 4’ 7, 9，13’ 17, 
18，22 and 24) were unmethylated at all Sacll, Eag\ and Sma\ sites of p16 exon 
1 (Table 6). They showed no methylation bands but two smaller fragments after 
digestion with EcoRl plus Sacll or Eag\ or Sma\ (Fig 2B, 2 C & 2 D respectively). 
Sixteen (67%) of our M M patients had hypermethylation at the Sacll site. They 
all showed retention of the 4.3 kb methylation bands together with the 3.3 and 
0.3 kb bands arising from the normal or unmethylated cells after digestion with 
EcoR\ and Sacll (Fig. 2B). With respect to the presence of tumor contents, the 
methylation band w a s prominent in twelve of them (No. 1-3，11-12, 14-16, 19-21 
and 23) and dominant in the other four (No. 5, 6, 8 and 10) (Fig. 2B). A s referred 
from Table 6，it is noteworthy that two (No. 5 and 6) of the latter samples were 
not methylated at the Eag\ site of p16. Moreover, none of our M M samples with 
repeated analyses, revealed methylation of the Sma\ site. The methylation 
89 
density of the p16 gene varies a m o n g our M M patients. According to Jones 
(1996), different methylation-sensitive restriction sites m a y be differentially 
methylated depending on the density and extensiveness of the methylation, 
which varies with the developmental stage of the specific tumor. Moreover, the 
level of transcriptional repression is dependent on methylation density. Partial 
methylation of C p G islands m a y result in down-regulation of the gene Involved. 
With progressive methylation, the gene m a y be totally inactivated. 
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Figure 3A 
Probe 
p ^ - 4 I D ~ • ~ / / T " ^ Z I > / A n : X I 
RlSmSa ^ ESm R1 
Sa  
S m • = f 3 
Sa = Sacll 
S m = Smal 
RI =EcoRl 
i U ^ I I _ Ecom 
_ | 0 . , 3.3kb I I _ 腿 編 
隱 I 0.55kb , _ _ I I _ 滅 / ~ 1 
0 過 I 3.3kb * — — 丨 丨 _ E c o m / E a g l * 
I 0.4kb , Q.65kb I “ _ 滅 胸 1 
| 0 . 4 k b | 3.3kb 1 丨丨_ 滅 / — 1 # 
Restriction map of p!6. Open boxes denote the three coding exons, the 
shaded box stands for the 3，untranslated region (UTR) oipl6. Exon 1 
resides in a 4.3 Kb EcoBJ restriction fragment. Methylation-sensitive, rare 
base-cutting restriction enzymes include three Smal (Sm), two 5acII (Sa), 
and two Eagl (E) sites. The location of PCR-generated probe used for 
Southern analysis is shown at the top. Below are the expected fragment 
sizes recognized by this probe when digested with the restriction enzymes 
shown in the normally unmethylated status. * The fragments produced by 
methylation of the 3’ Eagl site seen in normal tissue. # The fragments 
produced by methylation of the 3’ Smal stie seen in normal blood. 
(Adapted from Merlo et al, 1995) 
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6. 2. 4 Hypermethylation of p15 
Similarly, the restriction m a p of p15 is as shown in Figure 3B. With no 
methylation, two smaller fragments of 2.2 and 0.5 kb would result from the 
digestion by H/ndlU and the methylation-sensitive enzyme Eagl. However, if 
there is 5'CpG island methylation of p15 exon 1, a 2.8 kb restriction fragment 
would be produced. From the twenty-four patients studied, ten patients (No. 4, 
7，9,10, 15，17, 18, 20’ 21 and 24) were unmethylated. Al! showed no 
methylation bands but the 2.2 and 0.5 kb fragments (Fig. 2D). Fourteen patients 
(58%) had hypermethylation of p15 (Table 6). All revealed retention of the 2.8 
kb methylation bands with very strong signals and the 2.2 and 0.5 kb fragments. 
It thus appears that p15 w a s completely methylated in all samples showing 
methylation. 
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Figure 3B 
Probe 
- / / 丨二 :〒耀丨 1 y K ^ / / H ^ ^ _ M 
H3 B E S B H3 
m=Hindlll 
E =Eagl 
S =Sacll 
B =BssHll 
2.8kb 
~ / / — Hind III 
2.2 kb 0.5 kb 
~ " / / ‘ Hind III / Eag I 
Restriction map ofpl5. The probe used for Southern analysis is 
shown at the top. Exons 1 and 2 are depicted with noncoding 
regions shaded. Methylation-sensitive restriction enzyme sites and 
HindUl sites are shown in the region including exon 1. The 
predicted sizes of restriction fragments used to analyze the 
methylation status ofpI5 are shown at the bottom. (Adapted from 
Herman et al, reference 17) 
93 
6. 3 Hypermethylation of p16lp15 and 
clinico-pathologic correlation 
A s shown in Table 7A, w e found no homozygous deletions or gene 
rearrangements in any of our M M patients. However, high incidences of 
hypermethylation were detected in p16 or p15 (67% and 5 8 % respectively) or 
concomitantly (54%). Three patients showed hypermethylation of p16 (No. 
10,15 and 20) alone while seven others were unmethylated for both genes (No. 
4，7，9’ 17’ 18’ 22 and 24). Hypermethylation of p16 w a s found in 7 0 % and 5 7 % 
respectively a m o n g the pre-treated (n=17) and the post-treated (n=7) groups 
while that of p15 occurred in 5 3 % and 7 1 % a m o n g the pre- and post-treated 
groups (Table 7B). In the seven patients having blastic morphology (No. 2，6, 
10’ 11 15, 16 and 21), all (100%) showed methylation of p16, in contrast to the 
non-blastic group (n=17) in which p16 w a s observed in 5 3 % (p=0.026) (Table 
7C). However, p15 hypermethylaion in the blastic and non-blastic groups w a s 
observed in similar frequencies (57% V s 53%). All the seven unmethylated 
cases revealed non-blastic morphology (Table 4). All three patients (100%) 
having plasmacytomas (No. 3’ 5 and 11) were found to have concomitant 
hypermethylation of both p16 and p15 genes while this would only be seen in 
4 8 % of the non-plasmacytoma group (n=21)(Table 7D). 
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Table 7A p16 and p15 Status of MM patients 
Deletion (N=24) Methylation (N=24) 
p16 0% 67% 
p15 0% 58% 
Both 0% 54% 
Either 0% j m  
Table 7B Methylation and Treatment Status of MM patients 
Methylation Pre-Tx (N=17) Post-Tx (N=7) 
p16 70% 57% 
p15 53% 71% 
Both 53% 57% 
Either 70% 71% 
Tx: Treatment “ 
Table 7C Correlation of methvlation of o16/p15 
and blastic Morphology 
Methylation Blastic (N=7) Non-blastic (N=17) 
P16* 100% 53% 
P15 ^ 59% 
* p=0.026 “ 
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Table 7D Methylation and presence of plasmacytomas in MM 
Methylation Plasmacytoma (N=3) Non-plasmacytoma (n=21) 
p16 100% 62% 
p15 1 ^ 52% 
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Chapter 7 
Discussion 
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7.1 Absence of homozygous deletions, gene 
rearrangements and mutations in p16/p15 and Rb 
N o homozygous deletions or gene rearrangements were found by 
Southern blot analysis ofp16, p15 and Rb genes in the twenty-four M M patients 
studied. Using Polymerase Chain Reaction-Single Strand Conformation 
Polymorphism (PCR-SSCP), a sensitive method for the detection of point 
mutations in D N A fragments, no abnormal profiles were detected for p16 (exon 
1-3) and p15 (exon 1-2) in all cases. Our findings were consistent with that in 
the literature. Quesnel et al studied p16 gene on 18 and 30 patients with M M by 
Southern blot and P C R - S S C P analysis respectively, they detected no 
homozygous deletion on this gene and only two cases showed polymorphism. 
Hangaishi's group examined the status of p16, p15 and Rb genes in 6 patients 
with M M . None of them showed homozygous deletions or mutations of these 
three tumor suppressor genes. Frequent deletions of p16/p15 have been 
observed in lymphoid malignancies, particularly in pediatric A L L and B-Iineage 
subtype (Okuda et al., 1995; O g a w a et al., 1995). However, thus far, no 
deletions or mutations of p16 or p15 have been found in M M despite its B-
lineage origin (Ogawa et al., 1995; Quesnel et al., 1995; Stranks et al., 1995). 
Nevertheless, this m a y be consistent with the rarely observed loss of 
chromosome 9 or 9p in M M (Gould et al., 1988; V a n den Berghe, 1989; Ng et al 
in press, 1998). Previous cytogenetic findings showed that chromosomal gain of 
chromosome 9 w a s the predominant numeric changes in all the chromosomes 
studied. In all, m o n o s o m y 9 is the most rare (Zandecki et al, 1996). Recently, 
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our group also examined 18 Chinese M M patients by M G G / F I S H using D N A 
centromeric probes specific for chromosomes 3’ 7 and 9. W e demonstrated 
high incidences of polysomies (83%) and trisomies (89%) 9. M o n o s o m y 9 
occurred only at 5.6% {Ng et al, in press, 1998). W e m a y suggest that deletions 
ofp16/p15are rare. 
Residual p16, p15 or Rb signals in tumors contaminated by normal cells 
m a y pose technical problems in the detection of homozygous deletions of the 
genes. In general, the reliability of deletion detection drops with increased 
number of normal cells and hemizygous deletions are difficult tp determine and 
differentiate from non-deleted cases w h e n normal contaminants are more than 
3 0 % . In our patient samples, 4 2 % (10/24) of the cases had more than 7 0 % of 
the tumor cells. N o homozygous deletions were observed, although it is possible 
that it might be an underestimation. In this study w e only focused on the 
detection of homozygous deletions of p16, p15 and Rb genes. The incidence of 
hemizygous deletions of these genes w a s not evaluated. O n e of the reasons 
w a s that in our experience with Southern blot analysis, demonstrating of loss of 
only one copy of a gene in tumor cells contaminated by up to 2 0 % or over 3 0 % 
of normal residual cells is difficult. Furthermore, as for the tumor suppressor 
genes (see section on Knudson's Model), inactivation presumably requires the 
inactivation of both alleles, and the relevance of hemizygous deletions to the 
oncogenic process m a y be more hypothetical. 
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7. 2 Hypermethylation of p16/p15-an alternative way for gene 
inactivation 
Our study is the first demonstration that alterations of p16 and p15 
occurred at high incidences in multiple myeloma, not by homozygous deletions 
or mutations, but solely by hypermethylation of 5'CpG islands which m a y be a 
specific mechanism in this disease. This methylation pattern w a s not found in 
normal blood and normal marrow controls. Such high frequencies of 
involvement ofthese genes in M M m a k e them hitherto the most c o m m o n genetic 
abnormalities in this disease. Thus, these alterations m a y play an important role 
in the pathogenesis of M M . 
In our group of relatively high stage M M patients, high frequencies of 
involvement of either gene or concomitant were observed. However, since 
hypermethylation ofp16/p15vjas found in both low and high stage patients and 
in similar incidences in pre- and post-treated groups, it m a y suggest that they are 
early events in M M and their role in tumor initiation can be speculated. In line 
with this speculation is the evidence from studies with immortal but not 
tumorigenic m o u s e cell lines, supporting the idea that methylation changes occur 
very early in the transformation process (Jones,1996). The fact that concomitant 
hypermethylation of both p16 and p15 happened in all three cases of M M with 
plasmacytomas m a y underscore their pathogenetic significance in their 
development. Furthermore, the finding that all seven M M patients with blastic 
morphology revealed p16 hypermethylation (p=0.026) while all seven 
unmethylated cases had non-blastic morphology indicates that p16 
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hypermethylation m a y be associated with blastic disease. This is further 
supported by the absence of plasmacytoma and blastic morphology in all the 
unmethylated cases. In three cases, only the p16 gene was involved. This m a y 
suggest that p16 was the target gene in the pathogenesis in these cases. In one 
case, only the p15 gene was methylated which indicated that p15 m a y be the 
target for inactivation in the tumorigenesis in this particular case. 
7.2.1 Methylation of p15 gene 
Unlike solid tumors, the loss of p15 gene function is a rather dominant 
event in tumors derived from the hematopoietic cell system, and C p G island 
hypermethylation is by far the dominant mechanism involved. This is most 
dramatically apparent from large studies of patients with both the adult and 
childhood types of acute myelogenous leukemia (AML), in which 8 5 % and 6 5 % , 
respectively, of the non-cultured tumors have this change in the p15 gene 
(Herman et al, 1996; Herman et al, 1997). The methylation pattern seen forAML 
also predominates in adult A L L (71%) and pediatric B-cell A L L (48%) (Herman et 
al., 1996). No homozygous deletions or mutations of either the p15 or p16 
genes have been found in these studies, and the p16 gene w a s not 
simultaneously hypermethylated (Herman et al., 1996; Herman et al., 1997). 
Concomitant hypermethylation, u n c o m m o n thus so far in the literature of 
the study of p16 and p15 with the exception of Burkitt's lymphoma (50%), is a 
rather c o m m o n phenomenon in our patient group. Both p16 and p15 are 
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CDK4/6 inhibitors, which inhibit their interaction with D 1 cyclins and thus 
preventing the phosphorylation of the pRb and arresting the cell at Gi phase. 
p15 is up-regulated by transforming growth factor-p (TGF-p) which plays and 
important role in growth suppression of hematopoietic precursor cells in the bone 
marrow where most of the myeloma cells would be accumulated. This growth 
inhibitory activity of TGF-p has been shown actually effected through this p15 
regulation. In addition to p16, the inactivation of p15, which m a y be particularly 
important in bone marrow environment where there is increased TGF-p activity, 
would thus be critical in exerting the major up-stream inhibitory control of Rb 
function. This m a y also explain the need for concomitant hypermethylation of 
both p16 and p15 in M M . The consequent loss of cell cycle arrest and increased 
cellular proliferation would be further enhanced by the release of IL-6. 
7.2.2 Methylation of 5'-CpG island of p16/p15 
and lack of gene expression 
Other investigators have demonstrated that hypermethylation of 5'CpG 
islands ofp16/p15 can lead to transcriptional silencing proven by the absence of 
transcripts (Merlo et al, 1994; Herman et al, 1995). In vitro experiments have 
also demonstrated the reversible nature of this transcriptional block by the 
introduction of demethylation agent, 5-aza-2'-deoxycytidine, which leads to re-
expression of these genes. Aberrant methylation of p16 and p15 m a y be 
analogous to homozygous deletion, leading to loss of p16 and p15 expression 
respectively and a selective growth advantage to tumor cells. The association of 
hypermethylation and inactivation of these genes in M M has recently been 
102 
demonstrated by our group. W e investigated methylation status and 
transcription of these genes in six M M cell lines by Southern blot analysis and 
R T - P C R (Wong et al, in press, 1998). Aberrant methylation of p16 was found in 
all six M M cell lines studied. However, loss of p16 transcription was 
demonstrated only in four with extensive methylation in the 5' C p G islands. 
Conversely, only one M M cell line showed extensive methylation of p15, which 
was associated with p15 transcriptional block. Restoration of gene transcription 
was observed after treatment of the demethylating agent 5-aza-2'-deoxycytidine 
(Wong et al, in press, 1998). The above data show that the p16 and p15 genes 
are silenced in M M by hypermethylation of the 5' critical region and the loss of 
the gene transcripts can be reversible, consistent with findings in other tumors in 
the literature. 
7.2.3 Comparison of methylation status of primary samples and cell lines 
in MM 
Comparing the results from our primary M M samples and the cell lines, 
p16 hypermethylation occurred at high frequency (67% in primary samples and 
1 0 0 % in cell lines), whereas p15 hypermethylation w a s shown in only one of the 
M M cell lines (16%), but at a higher percentage (56%) in primary M M . This 
discrepancy m a y be due to the localization of plasma cells in bone marrow 
environment in the primary M M as suggested by the authors (Wong et al., in 
press, 1998). The primary M M specimens were all obtained from the bone 
marrow, where accumulated TGF-p would stimulate p15 expression and hence 
suppress tumor growth. It is possible that TGF-p m a y impose a selective 
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pressure upon inactivation of p15 expression in the bone marrow environment 
(Herman et al, 1996). However, M M cell lines were derived from different 
sources, including peripheral blood, bone marrow aspirates and pleural 
diffusions. It is also possible that cell lines m a y loss their methylation status after 
long period of in vitro cell line culture since in our in vitro culture system there is 
no TGF-p as supplement. 
In the cell line studies, transcriptional silencing of the p16 gene was only 
observed in four of the six M M cell lines where the 5' C p G islands of p16 was 
densely methylated. In contrast, p16 transcription was detected in the other two 
M M cell lines, which had p16 alleles with unmethylated sites as well as partially 
methylated sites. The cell line data support that the density of methylation in p16 
gene correlates with the level of gene transcription in M M . Unlike the cell line 
data, our primary samples showed no partial methylation patterns. Thus, this 
m a y suggest the complete loss of gene transcription of these genes in our 
primary M M cases. 
7.2.4 Progressive gene inactivation by 
random methylation errors 
For the progressive inactivation of tumor suppressor genes by abnormal 
methylation of C p G islands, tumor suppressor genes contain C p G islands which, 
in c o m m o n with other autosomal genes, are not normally methylated. R a n d o m 
methylation errors of these C p G sites leads to reduced gene expression, 
resulting in the clonal selection of cells with these heritable epigenetic defects. 
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Further methylation can result in the eventual paralysis of the gene by 
herochromatinization, giving rise to further selection of cells with methylation 
defects. Finally, focal hypermethylation of C p G islands on gene regulatory region 
occurs and leads to complete silencing the gene. Although w e do not presently 
understand whether de novo methylation of 5'CpG islands represents a random 
epigenetic alteration or occurs in a regulated manner, it seems likely that once 
methylation is established in the 5, regulatory region of a tumor suppressor gene, 
clonal selection will ensue leading to tumor progression. 
7.2.5 The lack of correlation of tumor contents revealed by the 
Southern blot analysis and morphologic assessment 
The problem of detection of specific gene deletions in primary tumor 
samples with normal cell contamination has been addressed previously. The 
examination of methylation of the 5'CpG islands of p16/p15 would be m u c h less 
affected by the presence of normal cells. This is because they would remain 
unmethylated and retention of a specific D N A fragment could only happen in 
hypermethylated genes from the tumor cells. However, the assessment of tumor 
infiltration on morphological ground has potential limitation by sampling variation 
that m a y lead to a lack of correlation with the tumor contents revealed by the 
Southern analysis. This fact is particularly important in M M as the disease itself 
tends to develop focally. Also, because gain in copy numbers of chromosome 9 
is a predominant phenomenon in M M by both cytogenetic and FISH studies, and 
the methylation status of the additional copies of chromosome 9 is variable 
there is a variable relationship between tumor cell numbers and the 
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chromosomal 9 D N A contents in the M M patients. A s demonstrated by our FISH 
study on M M cells, the variability of the percentages of cells with different 
polysomies of the s a m e and different chromosomes suggested the presence of 
heterogeneous populations of M M cells (Ng et al, in press, 1998). This 
heterogeneity m a y similarly exist in terms of the methylation status a m o n g the 
M M cells, which m a y further account for the lack of correlation between tumor 
contents revealed by the intensities of methylation signals and the morphologic 
evaluation. These various factors probably explain the discrepancies of tumor 
contents seen in s o m e cases (e.g. Nos. 5, 12’ 14 and 15). While morphological 
assessment gave them fairly low tumor percentages (25%-36%, Table 5), 
methylation occurred with the majority (>50%) of D N A . In these four cases, the 
morphological evaluation m a y probably under-estimate the tumor presence or 
the chromosome 9 D N A contents. 
7.3 Knudson's two-hit model of tumorigenesis 
According to Knudson's two-hit model of tumorigenesis, both copies of 
targeted tumor suppressor genes have to be inactivated. Allelic inactivation 
could be due to deletions, mutations or hypermethylation and a combination of 
these (e.g. homozygous deletion, hemizygous deletion and mutation or 
hypermethylation, etc.) occurring in both copies of a gene can finally lead to 
gene inactivation. Although frequent deletions of Rb (50-70%) have been 
identified in M M , a majority are hemizygous and not associated with lack of pRb 
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protein expression. Since bi-allelic loss of Rb and hence inactivation only occurs 
in 1 0 % of M M (Juge-Morineau et al, 1995), this m a y suggest that Rb is not the 
major target gene in M M . Dysregulation of R b function resulting from upstream 
control abnormalities can be speculated, and in fact, supported by our finding of 
a high frequency of (71%) p16/p15 hypermethylation (transcriptional repression 
or inactivation). 
7.4 Inverse relationship of p16 and Rb 
Complementary distribution of inactivation of both p16 and Rb genes have 
been quite well known. Only either of the two w a s inactivated in various tumors 
(Okamoto et al, 1994; Aagaard et al, 1995; Yeager et al, 1995; Shapiro et al, 
1995; Parry et al, 1995). If the genes involved in the up-stream control of Rb 
pathway have been inactivated, further inactivation of Rb m a y become 
redundant and confer no added growth advantage for clonal selection. 
Examples are best seen in lung carcinomas. While small cell lung cancers with 
frequent Rb inactivation rarely show p16 involvement, non-small cell lung 
cancers with rare Rb inactivation are more often found to have p16 inactivation 
(Merlo et al, 1995; Otterson et al, 1994). Our finding of inversely related 
alterations of Rb and p16/p15 in our primary M M cases further supports this 
notion. While hypermethylation (hence inactivation) of p16/p15 w a s found at 
high incidences, by Southern blot analysis, no homozygous deletions or gene 
rearrangements were observed on Rb. 
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Inactivation of both p16 and Rb genes had not been described in 
hematological malignancies until lately w h e n Hangaishi et al (Hangaishi et al, 
1996) reported four cases of primary lymphoid malignancies affected by 
simultaneous presence of homozygous deletion of p16 and loss of expression of 
pRb. This rare phenomenon m a y be explained on the other hand, as proposed 
by the authors, from several lines of evidences, which suggest that functional Rb 
protein is essential for cell cycle inhibition by p16 (Guan et al, 1994; Koh et al, 
1995; Lukas et al, 1995). p16 inactivation in a cell without functional Rb protein 
is not likely to confer an additional growth advantage upon the cell any more. In 
these double mutants, deletions might precede Rb inactivation, the latter could 
then contribute to advantageous tumor growth hereafter from a total cancellation 
of all the inhibitory effects of the other C D K s via Rb protein. The involvement of 
p16/p15 and Rb by Southern blot analysis and p R b expression were also studied 
on six cases of M M . N o homozygous deletions in p16/p15 or Rb or loss of p R b 
expression were observed. However, methylation status of p16/p15 in these M M 
cases w a s not evaluated. 
In the s a m e study on primary lymphoid malignancies, they observed that 
inactivation of the individual tumor-suppressor genes (MTSMp16, MTS2/p15 
p53, and Rb) seemed to occur independently to each other except for the p16 
and p15 genes. In addition, they suggested that disruptions of multiple tumor 
suppressors in a tumor cell confer an additional growth advantage on the tumor. 
This proposal m a y be in line with another school of thought, which supports that 
gene dosage effect might also be critically important for its tumor suppressor 
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function. Perhaps inactivation of a single allele m a y lead to a functional effect 
secondary to decreased expression due to haplo-insufficiency since the loss of 
one copy of the gene could partially abrogate its intrinsic functions. 
7. 5 Implications of our findings 
There are two implications for M M from our findings. 1. Since 
hypermethylation of p16/p15 is a c o m m o n event in M M , most patients can be 
benefited from this investigation. With Methylation-specific P C R technique as 
described by Baylin et al, the methylation status can serve as a tumor marker for 
the detection of minimal residual disease. More importantly, it m a y be used to 
check for tumor contamination in autologous bone marrow or peripheral stem cell 
harvests in autologous bone marrow transplantation. 2. It throws light on 
therapeutic innovations of M M treatment. U p till now, M M is still a uniformly fatal 
disease with chemotherapy. Use of demethylating agents either in vitro as a 
pretreatment of the autologous graft before transplantation or in vivo as a 
therapeutic agent incorporated into drug developments or via gene therapy by 
targeted delivery m a y be speculative at this stage but effective in future. 
7.6 Future studies 
1. To pursue on the studies as implicated in the last section on M M 
patients during autologous bone marrow transplantation or by longitudinal 
109 
investigation for the establishment of methylation status as a tumor marker for 
the evaluation of tumor contamination, minimal residual disease and patient's 
progress from treatment. 
2. Furthermore, if Rb is not the target gene as supported by our data 
above, another possibility of frequent hemizygous Rb deletion is due to the co-
deletion of an unidentified tumor suppressor gene residing on the 13q14 locus, 
which m a y be another target gene for M M . Similar observations of absence of 
Rb inactivation have been m a d e in s o m e other solid tumors with frequent loss of 
13q region where alternative target genes have been suggested (Maestro et al, 
1996; Cooney et al, 1996). Investigation of the loss of heterozygosity (LOH) 
using an Rb sequence polymorphism and polymorphic microsatellite markers 
surrounding the Rb gene on the long arm of chromosome 13 could be conducted 
for further mapping of the deleted region on chromosome 13q and localization of 
the potential alternative tumor suppressor gene other than Rb. 
3. Finally, to provide functional evidence in support of the hypothesis 
that p16/p15 genes are functional growth suppressor genes in M M , w e have to 
assess the growth suppressive function of these genes by gene transfer study. 
The effects of the introduction of full-length p16/p15 c D N A s into inactive p16/p15 
M M cell lines as compared to M M cell line with endogenous wild type p16/p15 
alleles could be examined. Marked growth suppression in the former as in 
contrast to the latter m a y be expected. 
1. Dl.Blood88:268, 1996 
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